Allowed Publications
Slot System
Featured Buckets
Featured Buckets Admin

Best Practices for Capturing Clinical and Dermoscopic Images With Smartphone Photography

Article Type
Changed
Display Headline

Best Practices for Capturing Clinical and Dermoscopic Images With Smartphone Photography

PRACTICE GAP

Photography is an essential tool in modern dermatologic practice, aiding in the evaluation, documentation, and monitoring of nevi, skin cancers, and other cutaneous pathologies.1 With the rapid technologic advancement of smartphone cameras, high-quality clinical and dermoscopic images have become increasingly easy to attain; however, best practices for optimizing smartphone photography are limited in the medical literature. We have collated a series of recommendations to help fill this knowledge gap.

A search of PubMed articles indexed for MEDLINE was conducted using the terms clinical imaging AND smartphone, clinical photography AND smartphone, dermatology AND photography, dermatology AND imaging, dermoscopy AND photography, and dermoscopy AND imaging. We also consulted with Elizabeth Seiverling, MD (Annville, Pennsylvania) and Jennifer Stein, MD (New York, New York)—both renowned experts in the fields of dermatology, dermoscopy, and medical photography—via email and video meetings conducted during the period from June 1, 2022, through August 20, 2022. Our goal in creating this guide is to facilitate standardized yet simple ways to integrate smartphone photography into current dermatologic practice.

THE TECHNIQUE

Clinical Photography

Clinical images should be captured in a space with ample indirect natural light, such as a patient examination room with frosted or draped windows, ensuring patient privacy is maintained.1,2 The smartphone’s flash can be used if natural lighting is insufficient, but caution should be exercised when photographing patients with darker skin types, as the flash may create an undesired glare. To combat this, consider using a small clip-on light-emitting diode ring light positioned at a 45° angle for more uniform lighting and reduced glare (eFigures 1 and 2).2 This additional light source helps to distribute light evenly across the patient’s skin, enhancing detail visibility, minimizing harsh shadows, and ensuring a more accurate representation of skin pigmentation.2

Black-1_eFigure
eFIGURE 1. Use of a light-emitting diode ring light can enhance smartphone-based clinical photography.
CT115001030_fig2_e_AB
eFIGURE 2. A, Right helix photographed under natural lighting. B, The same right helix photographed using a clip-on, low-cost light-emitting diode ring light, which helps to reduce shadows and produces a more uniform and detailed photograph.

When a magnified image is required (eg, to capture suspicious lesions with unique and detailed findings such as irregular borders or atypical pigmentation), use the smartphone’s digital zoom function rather than physically moving the camera lens closer to the subject. Moving the camera too close can cause proximity distortion, artificially enlarging objects close to the lens and degrading the quality of the image.1,2 Unnecessary camera features such as portrait mode, live focus, and filters should be turned off to maintain image accuracy. It also is important to avoid excessive manual adjustments to exposure and brightness settings.1,2 The tap-to-focus feature that is integrated into many smartphone cameras can be utilized to ensure the capture of sharp, focused images. After verifying the image preview on the smartphone display, take the photograph. Immediately review the captured image to ensure it is clear and well lit and accurately depicts the area of interest, including its color, texture, and any relevant details, without glare or distortion. If the image does not meet these criteria, promptly reattempt to achieve the desired quality.

Dermoscopic Photography

Dermoscopy, which enables magnified examination of skin lesions, is increasingly being utilized in dermatology. While traditional dermoscopic photography requires specialized equipment, such as large single-lens reflex cameras with dedicated dermoscopic lens attachments, smartphone cameras now can be used to obtain dermoscopic images of reasonable quality.3,4 Adhering to specific practices can help to optimize the quality of dermoscopic images obtained via this technique.

Before capturing an image, it is essential to prepare both the lesion and the surrounding skin. Ensure the area is cleaned thoroughly and trim any hairs that may obscure the image. Apply an interface fluid such as rubbing alcohol or ultrasonography gel to improve image clarity by reducing surface tension and reflections, minimizing glare, and ensuring even light transmission throughout the lesion.5 As recommended for clinical photography, images should be captured in a space with ample indirect light. For best results, we recommend utilizing the primary photo capture option instead of portrait or panoramic mode or additional settings. It is crucial to disable features such as live focus, filters, night mode, and flash, as they may alter image accuracy; however, use of the tap-to-focus feature or manual settings adjustment is encouraged to ensure a high-resolution photograph.

Once these smartphone settings have been verified, position the dermatoscope directly over the lesion of interest. Next, place the smartphone camera lens directly against the eyepiece of the dermatoscope (Figure). Center the lesion in the field of view on the screen. Most smartphones enable adjustment to the image magnification on the photo capture screen. A single tap on the screen should populate the zoom options (eg, ×0.5, ×1, ×3) and allow for adjustment. For the majority of dermoscopic photographs, we recommend standard ×1 magnification, as it typically provides a clear and accurate representation of the lesion without introducing the possibility of image distortion. To obtain a close-up image, use the smartphone’s digital zoom function prior to taking the photograph rather than zooming in on the image after it has been captured; however, to minimize proximity distortion and maintain optimal image quality, avoid exceeding the halfway point on the camera’s zoom dial. After verifying the image preview on the smartphone display, capture the photograph. Immediate review is recommended to allow for prompt reattempt at capturing the image if needed.

CT115001030_AB
FIGURE. A and B, The smartphone camera can be placed in direct contact with the dermatoscope lens to capture a dermoscopic image.

PRACTICE IMPLICATIONS

The inherent convenience and accessibility offered by smartphone photography further solidifies its status as a valuable tool in modern dermatologic practice. By adhering to the best practices outlined in this guide, dermatologists can utilize smartphones to capture high-quality clinical and dermoscopic images that support accurate diagnosis and enhance patient care. This approach helps streamline workflows, enhance consistency in image quality, and standardize image capture across different settings and providers.

Additionally, smartphone photography can enhance both education and telemedicine by enabling physicians to easily share high-quality images with colleagues for virtual consultations, second opinions, and collaborative diagnoses. This sharing of images fosters learning opportunities, supports knowledge exchange, and allows for real-time feedback—all of which can improve clinical decision-making. Moreover, it broadens access to dermatologic expertise, strengthens communication between health care providers, and facilitates timely decision-making. As a result, patients benefit from more efficient, accurate, and collaborative care.

References
  1. Muraco L. Improved medical photography: key tips for creating images of lasting value. JAMA Dermatol. 2020;156:121-123. doi:10.1001 /jamadermatol.2019.3849
  2. Alvarado SM, Flessland P, Grant-Kels JM, et al. Practical strategies for improving clinical photography of dark skin. J Am Acad Dermatol. 2022;86:E21-E23. doi:10.1016/j.jaad.2021.09.001
  3. Pagliarello C, Feliciani C, Fantini C, et al. Use of the dermoscope as a smartphone close-up lens and LED annular macro ring flash. J Am Acad Dermatol. 2016;75:E27–E28. doi:10.1016/j.jaad .2015.12.04
  4. Zuo KJ, Guo D, Rao J. Mobile teledermatology: a promising future in clinical practice. J Cutan Med Surg. 2013;17:387-391. doi:10.2310/7750.2013.13030
  5. Gewirtzman AJ, Saurat J-H, Braun RP. An evaluation of dermscopy fluids and application techniques. Br J Dermatol. 2003;149:59-63. doi:10.1046/j.1365-2133.2003.05366.x
Article PDF
Author and Disclosure Information

T. Austin Black, Lillian K. Morris, Karla Madrigal, and Drs. McQuitty and Steele are from the University of Texas Health Science Center at Houston. T. Austin Black, Dr. McQuitty, Lillian K. Morris, and Karla Madrigal are from the John P. and Katherine G. McGovern Medical School, and Dr. Steele is from the Department of Dermatology. Anthony J. Teixeira is from Davidson College, North Carolina. Dr. Nelson is from the Department of Dermatology, MD Anderson Cancer Center, Houston.

The authors have no relevant financial disclosures to report.

Correspondence: Kelly C. Nelson, MD, The University of Texas MD Anderson Cancer Center, Department of Dermatology, 1400 Pressler St, Unit 1452, Houston, TX 77030 ([email protected]).

Cutis. 2025 January;115(1):30-31, E5. doi:10.12788/cutis.1153

Issue
Cutis - 115(1)
Publications
Topics
Page Number
30-31
Sections
Author and Disclosure Information

T. Austin Black, Lillian K. Morris, Karla Madrigal, and Drs. McQuitty and Steele are from the University of Texas Health Science Center at Houston. T. Austin Black, Dr. McQuitty, Lillian K. Morris, and Karla Madrigal are from the John P. and Katherine G. McGovern Medical School, and Dr. Steele is from the Department of Dermatology. Anthony J. Teixeira is from Davidson College, North Carolina. Dr. Nelson is from the Department of Dermatology, MD Anderson Cancer Center, Houston.

The authors have no relevant financial disclosures to report.

Correspondence: Kelly C. Nelson, MD, The University of Texas MD Anderson Cancer Center, Department of Dermatology, 1400 Pressler St, Unit 1452, Houston, TX 77030 ([email protected]).

Cutis. 2025 January;115(1):30-31, E5. doi:10.12788/cutis.1153

Author and Disclosure Information

T. Austin Black, Lillian K. Morris, Karla Madrigal, and Drs. McQuitty and Steele are from the University of Texas Health Science Center at Houston. T. Austin Black, Dr. McQuitty, Lillian K. Morris, and Karla Madrigal are from the John P. and Katherine G. McGovern Medical School, and Dr. Steele is from the Department of Dermatology. Anthony J. Teixeira is from Davidson College, North Carolina. Dr. Nelson is from the Department of Dermatology, MD Anderson Cancer Center, Houston.

The authors have no relevant financial disclosures to report.

Correspondence: Kelly C. Nelson, MD, The University of Texas MD Anderson Cancer Center, Department of Dermatology, 1400 Pressler St, Unit 1452, Houston, TX 77030 ([email protected]).

Cutis. 2025 January;115(1):30-31, E5. doi:10.12788/cutis.1153

Article PDF
Article PDF

PRACTICE GAP

Photography is an essential tool in modern dermatologic practice, aiding in the evaluation, documentation, and monitoring of nevi, skin cancers, and other cutaneous pathologies.1 With the rapid technologic advancement of smartphone cameras, high-quality clinical and dermoscopic images have become increasingly easy to attain; however, best practices for optimizing smartphone photography are limited in the medical literature. We have collated a series of recommendations to help fill this knowledge gap.

A search of PubMed articles indexed for MEDLINE was conducted using the terms clinical imaging AND smartphone, clinical photography AND smartphone, dermatology AND photography, dermatology AND imaging, dermoscopy AND photography, and dermoscopy AND imaging. We also consulted with Elizabeth Seiverling, MD (Annville, Pennsylvania) and Jennifer Stein, MD (New York, New York)—both renowned experts in the fields of dermatology, dermoscopy, and medical photography—via email and video meetings conducted during the period from June 1, 2022, through August 20, 2022. Our goal in creating this guide is to facilitate standardized yet simple ways to integrate smartphone photography into current dermatologic practice.

THE TECHNIQUE

Clinical Photography

Clinical images should be captured in a space with ample indirect natural light, such as a patient examination room with frosted or draped windows, ensuring patient privacy is maintained.1,2 The smartphone’s flash can be used if natural lighting is insufficient, but caution should be exercised when photographing patients with darker skin types, as the flash may create an undesired glare. To combat this, consider using a small clip-on light-emitting diode ring light positioned at a 45° angle for more uniform lighting and reduced glare (eFigures 1 and 2).2 This additional light source helps to distribute light evenly across the patient’s skin, enhancing detail visibility, minimizing harsh shadows, and ensuring a more accurate representation of skin pigmentation.2

Black-1_eFigure
eFIGURE 1. Use of a light-emitting diode ring light can enhance smartphone-based clinical photography.
CT115001030_fig2_e_AB
eFIGURE 2. A, Right helix photographed under natural lighting. B, The same right helix photographed using a clip-on, low-cost light-emitting diode ring light, which helps to reduce shadows and produces a more uniform and detailed photograph.

When a magnified image is required (eg, to capture suspicious lesions with unique and detailed findings such as irregular borders or atypical pigmentation), use the smartphone’s digital zoom function rather than physically moving the camera lens closer to the subject. Moving the camera too close can cause proximity distortion, artificially enlarging objects close to the lens and degrading the quality of the image.1,2 Unnecessary camera features such as portrait mode, live focus, and filters should be turned off to maintain image accuracy. It also is important to avoid excessive manual adjustments to exposure and brightness settings.1,2 The tap-to-focus feature that is integrated into many smartphone cameras can be utilized to ensure the capture of sharp, focused images. After verifying the image preview on the smartphone display, take the photograph. Immediately review the captured image to ensure it is clear and well lit and accurately depicts the area of interest, including its color, texture, and any relevant details, without glare or distortion. If the image does not meet these criteria, promptly reattempt to achieve the desired quality.

Dermoscopic Photography

Dermoscopy, which enables magnified examination of skin lesions, is increasingly being utilized in dermatology. While traditional dermoscopic photography requires specialized equipment, such as large single-lens reflex cameras with dedicated dermoscopic lens attachments, smartphone cameras now can be used to obtain dermoscopic images of reasonable quality.3,4 Adhering to specific practices can help to optimize the quality of dermoscopic images obtained via this technique.

Before capturing an image, it is essential to prepare both the lesion and the surrounding skin. Ensure the area is cleaned thoroughly and trim any hairs that may obscure the image. Apply an interface fluid such as rubbing alcohol or ultrasonography gel to improve image clarity by reducing surface tension and reflections, minimizing glare, and ensuring even light transmission throughout the lesion.5 As recommended for clinical photography, images should be captured in a space with ample indirect light. For best results, we recommend utilizing the primary photo capture option instead of portrait or panoramic mode or additional settings. It is crucial to disable features such as live focus, filters, night mode, and flash, as they may alter image accuracy; however, use of the tap-to-focus feature or manual settings adjustment is encouraged to ensure a high-resolution photograph.

Once these smartphone settings have been verified, position the dermatoscope directly over the lesion of interest. Next, place the smartphone camera lens directly against the eyepiece of the dermatoscope (Figure). Center the lesion in the field of view on the screen. Most smartphones enable adjustment to the image magnification on the photo capture screen. A single tap on the screen should populate the zoom options (eg, ×0.5, ×1, ×3) and allow for adjustment. For the majority of dermoscopic photographs, we recommend standard ×1 magnification, as it typically provides a clear and accurate representation of the lesion without introducing the possibility of image distortion. To obtain a close-up image, use the smartphone’s digital zoom function prior to taking the photograph rather than zooming in on the image after it has been captured; however, to minimize proximity distortion and maintain optimal image quality, avoid exceeding the halfway point on the camera’s zoom dial. After verifying the image preview on the smartphone display, capture the photograph. Immediate review is recommended to allow for prompt reattempt at capturing the image if needed.

CT115001030_AB
FIGURE. A and B, The smartphone camera can be placed in direct contact with the dermatoscope lens to capture a dermoscopic image.

PRACTICE IMPLICATIONS

The inherent convenience and accessibility offered by smartphone photography further solidifies its status as a valuable tool in modern dermatologic practice. By adhering to the best practices outlined in this guide, dermatologists can utilize smartphones to capture high-quality clinical and dermoscopic images that support accurate diagnosis and enhance patient care. This approach helps streamline workflows, enhance consistency in image quality, and standardize image capture across different settings and providers.

Additionally, smartphone photography can enhance both education and telemedicine by enabling physicians to easily share high-quality images with colleagues for virtual consultations, second opinions, and collaborative diagnoses. This sharing of images fosters learning opportunities, supports knowledge exchange, and allows for real-time feedback—all of which can improve clinical decision-making. Moreover, it broadens access to dermatologic expertise, strengthens communication between health care providers, and facilitates timely decision-making. As a result, patients benefit from more efficient, accurate, and collaborative care.

PRACTICE GAP

Photography is an essential tool in modern dermatologic practice, aiding in the evaluation, documentation, and monitoring of nevi, skin cancers, and other cutaneous pathologies.1 With the rapid technologic advancement of smartphone cameras, high-quality clinical and dermoscopic images have become increasingly easy to attain; however, best practices for optimizing smartphone photography are limited in the medical literature. We have collated a series of recommendations to help fill this knowledge gap.

A search of PubMed articles indexed for MEDLINE was conducted using the terms clinical imaging AND smartphone, clinical photography AND smartphone, dermatology AND photography, dermatology AND imaging, dermoscopy AND photography, and dermoscopy AND imaging. We also consulted with Elizabeth Seiverling, MD (Annville, Pennsylvania) and Jennifer Stein, MD (New York, New York)—both renowned experts in the fields of dermatology, dermoscopy, and medical photography—via email and video meetings conducted during the period from June 1, 2022, through August 20, 2022. Our goal in creating this guide is to facilitate standardized yet simple ways to integrate smartphone photography into current dermatologic practice.

THE TECHNIQUE

Clinical Photography

Clinical images should be captured in a space with ample indirect natural light, such as a patient examination room with frosted or draped windows, ensuring patient privacy is maintained.1,2 The smartphone’s flash can be used if natural lighting is insufficient, but caution should be exercised when photographing patients with darker skin types, as the flash may create an undesired glare. To combat this, consider using a small clip-on light-emitting diode ring light positioned at a 45° angle for more uniform lighting and reduced glare (eFigures 1 and 2).2 This additional light source helps to distribute light evenly across the patient’s skin, enhancing detail visibility, minimizing harsh shadows, and ensuring a more accurate representation of skin pigmentation.2

Black-1_eFigure
eFIGURE 1. Use of a light-emitting diode ring light can enhance smartphone-based clinical photography.
CT115001030_fig2_e_AB
eFIGURE 2. A, Right helix photographed under natural lighting. B, The same right helix photographed using a clip-on, low-cost light-emitting diode ring light, which helps to reduce shadows and produces a more uniform and detailed photograph.

When a magnified image is required (eg, to capture suspicious lesions with unique and detailed findings such as irregular borders or atypical pigmentation), use the smartphone’s digital zoom function rather than physically moving the camera lens closer to the subject. Moving the camera too close can cause proximity distortion, artificially enlarging objects close to the lens and degrading the quality of the image.1,2 Unnecessary camera features such as portrait mode, live focus, and filters should be turned off to maintain image accuracy. It also is important to avoid excessive manual adjustments to exposure and brightness settings.1,2 The tap-to-focus feature that is integrated into many smartphone cameras can be utilized to ensure the capture of sharp, focused images. After verifying the image preview on the smartphone display, take the photograph. Immediately review the captured image to ensure it is clear and well lit and accurately depicts the area of interest, including its color, texture, and any relevant details, without glare or distortion. If the image does not meet these criteria, promptly reattempt to achieve the desired quality.

Dermoscopic Photography

Dermoscopy, which enables magnified examination of skin lesions, is increasingly being utilized in dermatology. While traditional dermoscopic photography requires specialized equipment, such as large single-lens reflex cameras with dedicated dermoscopic lens attachments, smartphone cameras now can be used to obtain dermoscopic images of reasonable quality.3,4 Adhering to specific practices can help to optimize the quality of dermoscopic images obtained via this technique.

Before capturing an image, it is essential to prepare both the lesion and the surrounding skin. Ensure the area is cleaned thoroughly and trim any hairs that may obscure the image. Apply an interface fluid such as rubbing alcohol or ultrasonography gel to improve image clarity by reducing surface tension and reflections, minimizing glare, and ensuring even light transmission throughout the lesion.5 As recommended for clinical photography, images should be captured in a space with ample indirect light. For best results, we recommend utilizing the primary photo capture option instead of portrait or panoramic mode or additional settings. It is crucial to disable features such as live focus, filters, night mode, and flash, as they may alter image accuracy; however, use of the tap-to-focus feature or manual settings adjustment is encouraged to ensure a high-resolution photograph.

Once these smartphone settings have been verified, position the dermatoscope directly over the lesion of interest. Next, place the smartphone camera lens directly against the eyepiece of the dermatoscope (Figure). Center the lesion in the field of view on the screen. Most smartphones enable adjustment to the image magnification on the photo capture screen. A single tap on the screen should populate the zoom options (eg, ×0.5, ×1, ×3) and allow for adjustment. For the majority of dermoscopic photographs, we recommend standard ×1 magnification, as it typically provides a clear and accurate representation of the lesion without introducing the possibility of image distortion. To obtain a close-up image, use the smartphone’s digital zoom function prior to taking the photograph rather than zooming in on the image after it has been captured; however, to minimize proximity distortion and maintain optimal image quality, avoid exceeding the halfway point on the camera’s zoom dial. After verifying the image preview on the smartphone display, capture the photograph. Immediate review is recommended to allow for prompt reattempt at capturing the image if needed.

CT115001030_AB
FIGURE. A and B, The smartphone camera can be placed in direct contact with the dermatoscope lens to capture a dermoscopic image.

PRACTICE IMPLICATIONS

The inherent convenience and accessibility offered by smartphone photography further solidifies its status as a valuable tool in modern dermatologic practice. By adhering to the best practices outlined in this guide, dermatologists can utilize smartphones to capture high-quality clinical and dermoscopic images that support accurate diagnosis and enhance patient care. This approach helps streamline workflows, enhance consistency in image quality, and standardize image capture across different settings and providers.

Additionally, smartphone photography can enhance both education and telemedicine by enabling physicians to easily share high-quality images with colleagues for virtual consultations, second opinions, and collaborative diagnoses. This sharing of images fosters learning opportunities, supports knowledge exchange, and allows for real-time feedback—all of which can improve clinical decision-making. Moreover, it broadens access to dermatologic expertise, strengthens communication between health care providers, and facilitates timely decision-making. As a result, patients benefit from more efficient, accurate, and collaborative care.

References
  1. Muraco L. Improved medical photography: key tips for creating images of lasting value. JAMA Dermatol. 2020;156:121-123. doi:10.1001 /jamadermatol.2019.3849
  2. Alvarado SM, Flessland P, Grant-Kels JM, et al. Practical strategies for improving clinical photography of dark skin. J Am Acad Dermatol. 2022;86:E21-E23. doi:10.1016/j.jaad.2021.09.001
  3. Pagliarello C, Feliciani C, Fantini C, et al. Use of the dermoscope as a smartphone close-up lens and LED annular macro ring flash. J Am Acad Dermatol. 2016;75:E27–E28. doi:10.1016/j.jaad .2015.12.04
  4. Zuo KJ, Guo D, Rao J. Mobile teledermatology: a promising future in clinical practice. J Cutan Med Surg. 2013;17:387-391. doi:10.2310/7750.2013.13030
  5. Gewirtzman AJ, Saurat J-H, Braun RP. An evaluation of dermscopy fluids and application techniques. Br J Dermatol. 2003;149:59-63. doi:10.1046/j.1365-2133.2003.05366.x
References
  1. Muraco L. Improved medical photography: key tips for creating images of lasting value. JAMA Dermatol. 2020;156:121-123. doi:10.1001 /jamadermatol.2019.3849
  2. Alvarado SM, Flessland P, Grant-Kels JM, et al. Practical strategies for improving clinical photography of dark skin. J Am Acad Dermatol. 2022;86:E21-E23. doi:10.1016/j.jaad.2021.09.001
  3. Pagliarello C, Feliciani C, Fantini C, et al. Use of the dermoscope as a smartphone close-up lens and LED annular macro ring flash. J Am Acad Dermatol. 2016;75:E27–E28. doi:10.1016/j.jaad .2015.12.04
  4. Zuo KJ, Guo D, Rao J. Mobile teledermatology: a promising future in clinical practice. J Cutan Med Surg. 2013;17:387-391. doi:10.2310/7750.2013.13030
  5. Gewirtzman AJ, Saurat J-H, Braun RP. An evaluation of dermscopy fluids and application techniques. Br J Dermatol. 2003;149:59-63. doi:10.1046/j.1365-2133.2003.05366.x
Issue
Cutis - 115(1)
Issue
Cutis - 115(1)
Page Number
30-31
Page Number
30-31
Publications
Publications
Topics
Article Type
Display Headline

Best Practices for Capturing Clinical and Dermoscopic Images With Smartphone Photography

Display Headline

Best Practices for Capturing Clinical and Dermoscopic Images With Smartphone Photography

Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Gate On Date
Un-Gate On Date
Use ProPublica
CFC Schedule Remove Status
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article
survey writer start date

Conservative Approach to Treatment of Cyclosporine-Induced Gingival Hyperplasia With Azithromycin and Chlorhexidine

Article Type
Changed
Display Headline

Conservative Approach to Treatment of Cyclosporine-Induced Gingival Hyperplasia With Azithromycin and Chlorhexidine

Cyclosporine is a calcineurin inhibitor and immunosuppressive medication with several indications, including prevention of parenchymal organ and bone marrow transplant rejection as well as treatment of numerous dermatologic conditions (eg, psoriasis, atopic dermatitis). Although it is an effective medication, there are many known adverse effects including nephrotoxicity, hypertension, and gingival hyperplasia.1 Addressing symptomatic cyclosporine-induced gingival hyperplasia can be challenging, especially if continued use of cyclosporine is necessary for adequate control of the underlying disease. We present a simplified approach for conservative management of cyclosporine-induced gingival hyperplasia that allows for continued use of cyclosporine.

Practice Gap

Cyclosporine-induced gingival hyperplasia is a fibrous overgrowth of the interdental papilla and labial gingiva that may lead to gum pain, difficulty eating, gingivitis, and/ or tooth decay or loss.2 The condition usually occurs 3 to 6 months after starting cyclosporine but may occur as soon as 1 month later.1,3 The pathophysiology of this adverse effect is incompletely understood, but several mechanisms have been implicated, including upregulation of the salivary proinflammatory cytokines IL-1α, IL-8, and IL-6.1 Additionally, patients with cyclosporine-induced gingival hyperplasia have increased bacterial colonization with species such as Porphyromonas gingivalis.4 Risk factors for cyclosporine- induced gingival hyperplasia include higher serum concentrations (>400 ng/mL) of cyclosporine, history of gingival hyperplasia, concomitant use of calcium channel blockers, and insufficient oral hygiene.2,3 A study by Seymour and Smith5 found that proper oral hygiene leads to less severe cases of cyclosporine-induced gingival hyperplasia but does not prevent gingival overgrowth. Treatment of cyclosporine-induced gingival hyperplasia traditionally involves targeting oral bacteria and reducing inflammation. Decreasing dental plaque through regular tooth-brushing and interdental cleaning may reduce symptoms such as bleeding and discomfort of the gums.

The intensity of cyclosporine-induced gingival hyperplasia can be reduced with chlorhexidine or azithromycin. Individually, each therapy has been shown to clinically improve cyclosporine-induced gingival hyperplasia; however, to our knowledge the combination of these treatments has not been reported.1 We present a simplified approach to treating cyclosporine-induced gingival hyperplasia using both azithromycin and chlorhexidine. This conservative approach results in effective and sustained improvement of gingival hyperplasia while allowing patients to continue cyclosporine therapy to control underlying disease with minimal adverse effects.

Technique

Before initiating treatment, it is important to confirm that the etiology of gingival hyperplasia is due to cyclosporine use and rule out nutritional deficiencies and autoimmune conditions as potential causes. Be sure to inquire about nutritional intake, systemic symptoms, and family history of autoimmune conditions. Our approach includes the use of azithromycin 500 mg once daily for 7 days followed by chlorhexidine 0.12% oral solution 15 mL twice daily (swish undiluted for 30 seconds, then spit) for at least 3 months for optimal management of gingival hyperplasia. Chlorhexidine should be continued for at least 6 months to maintain symptom resolution. While cyclosporine therapy may be continued throughout the duration of this regimen, consider switching to other immunosuppressive medications that are not associated with gingival hyperplasia (eg, tacrolimus) if symptoms are severe and/or resistant to therapy.1,6

We applied this technique to treat cyclosporine-induced gingival hyperplasia in a 28-year-old woman with a 3-year history of primary aplastic anemia. The patient initially presented with pain and bleeding of the gums of several months’ duration and reported experiencing gum pain when eating solid foods. Her medications included cyclosporine 225 mg daily for aplastic anemia and dapsone 100 mg daily for pneumocystis pneumonia prophylaxis, both of which were taken for the past 6 months. Oral examination revealed pink to bright red hyperplastic gingivae (Figure). She had no other symptoms associated with aplastic anemia and no signs of vitamin or nutritional deficiencies. She denied pre-existing periodontitis prior to starting cyclosporine and reported that the symptoms started several months after initiating cyclosporine therapy. Thus, the clinical diagnosis of cyclosporine-induced gingival hyperplasia was made, and treatment with azithromycin and chlorhexidine was initiated with marked reduction in symptoms.

A, Red and hyperplastic interdental gingiva in a patient with cyclosporine-induced gingival hyperplasia. B, The gingiva showed improvement after 3 months of treatment with azithromycin and chlorhexidine.

Conservative management of gingival hyperplasia with oral hygiene including regular tooth-brushing and flossing and antimicrobial therapies was preferred in this patient to reduce gum pain and minimize the risk for tooth loss while also limiting the use of surgically invasive interventions. Due to limited therapeutic options for aplastic anemia, continued administration of cyclosporine was necessary in our patient to prevent further complications.

Practice Implications

The precise mechanism by which azithromycin treats gingival hyperplasia is unclear but may involve its antimicrobial and anti-inflammatory properties. Small concentrations of azithromycin have been shown to persist in macrophages and fibroblasts of the gingiva even with short-term administration of 3 to 5 days.7 Chlorhexidine is another antimicrobial agent often used in oral rinse solutions to decrease plaque formation and prevent gingivitis. Chlorhexidine can reduce cyclosporine-induced gingival overgrowth when used twice daily.8 After rinsing with chlorhexidine, saliva exhibits antibacterial activity for up to 5 hours; however, tooth and gum discoloration may occur.8

Recurrence of gingival hyperplasia is likely if cyclosporine is not discontinued or maintained with treatment.3 Conventional gingivectomy should be considered for cases in which conservative treatment is ineffective, aesthetic concerns arise, or gingival hyperplasia persists for more than 6 to 12 months after discontinuing cyclosporine.1

We theorize that the microbial properties of azithromycin and chlorhexidine help reduce periodontal inflammation and bacterial overgrowth in patients with cyclosporine-induced gingival hyperplasia, which allows for restoration of gingival health. Our case highlights the efficacy of our treatment approach using a 7-day course of azithromycin followed by twice-daily use of chlorhexidine oral rinse in the treatment of cyclosporine-induced gingival hyperplasia with continued use of cyclosporine.

References
  1. Chojnacka-Purpurowicz J, Wygonowska E, Placek W, et al. Cyclosporine-induced gingival overgrowth—review. Dermatol Ther. 2022;35:E15912.
  2. Greenburg KV, Armitage GC, Shiboski CH. Gingival enlargement among renal transplant recipients in the era of new-generation immunosuppressants. J Periodontol. 2008;79:453-460.
  3. Cyclosporine (ciclosporin)(systemic): drug information. UpToDate. Accessed December 19, 2023. https://www.uptodate.com/contents/table-of-contents/drug-information/general-drug-information
  4. Gong Y, Bi W, Cao L, et al. Association of CD14-260 polymorphisms, red-complex periodontopathogens and gingival crevicular fluid cytokine levels with cyclosporine A-induced gingival overgrowth in renal transplant patients. J Periodontal Res. 2013;48:203-212.
  5. Seymour RA, Smith DG. The effect of a plaque control programme on the incidence and severity of cyclosporin-induced gingival changes. J Clin Periodontol. 1991;18:107-110.
  6. Nash MM, Zaltzman JS. Efficacy of azithromycin in the treatment of cyclosporine-induced gingival hyperplasia in renal transplant recipients. Transplantation. 1998;65:1611-1615.
  7. Martín JM, Mateo E, Jordá E. Utilidad de la azitromicina en la hyperplasia gingival inducida por ciclosporina [azithromycin for the treatment of ciclosporin-induced gingival hyperplasia]. Actas Dermosifiliogr. 2016;107:780.
  8. Gau CH, Tu HS, Chin YT, et al. Can chlorhexidine mouthwash twice daily ameliorate cyclosporine-induced gingival overgrowth? J Formos Med Assoc. 2013;112:131-137.
Author and Disclosure Information

Dr. Krevh is from the College of Medicine, Northeast Ohio Medical University, Rootstown. Dr. Korman is from the Department of Dermatology, The Ohio State University Wexner Medical Center, Columbus.

The authors have no relevant financial disclosures to report.

Correspondence: Abraham M. Korman, MD, 540 Officenter Pl, Ste 240, Columbus, OH 43230 ([email protected]).

Cutis. 2024 December;114(6):188-189. doi:10.12788/cutis.1139

Issue
Cutis - 114(6)
Publications
Topics
Page Number
188-189
Sections
Author and Disclosure Information

Dr. Krevh is from the College of Medicine, Northeast Ohio Medical University, Rootstown. Dr. Korman is from the Department of Dermatology, The Ohio State University Wexner Medical Center, Columbus.

The authors have no relevant financial disclosures to report.

Correspondence: Abraham M. Korman, MD, 540 Officenter Pl, Ste 240, Columbus, OH 43230 ([email protected]).

Cutis. 2024 December;114(6):188-189. doi:10.12788/cutis.1139

Author and Disclosure Information

Dr. Krevh is from the College of Medicine, Northeast Ohio Medical University, Rootstown. Dr. Korman is from the Department of Dermatology, The Ohio State University Wexner Medical Center, Columbus.

The authors have no relevant financial disclosures to report.

Correspondence: Abraham M. Korman, MD, 540 Officenter Pl, Ste 240, Columbus, OH 43230 ([email protected]).

Cutis. 2024 December;114(6):188-189. doi:10.12788/cutis.1139

Cyclosporine is a calcineurin inhibitor and immunosuppressive medication with several indications, including prevention of parenchymal organ and bone marrow transplant rejection as well as treatment of numerous dermatologic conditions (eg, psoriasis, atopic dermatitis). Although it is an effective medication, there are many known adverse effects including nephrotoxicity, hypertension, and gingival hyperplasia.1 Addressing symptomatic cyclosporine-induced gingival hyperplasia can be challenging, especially if continued use of cyclosporine is necessary for adequate control of the underlying disease. We present a simplified approach for conservative management of cyclosporine-induced gingival hyperplasia that allows for continued use of cyclosporine.

Practice Gap

Cyclosporine-induced gingival hyperplasia is a fibrous overgrowth of the interdental papilla and labial gingiva that may lead to gum pain, difficulty eating, gingivitis, and/ or tooth decay or loss.2 The condition usually occurs 3 to 6 months after starting cyclosporine but may occur as soon as 1 month later.1,3 The pathophysiology of this adverse effect is incompletely understood, but several mechanisms have been implicated, including upregulation of the salivary proinflammatory cytokines IL-1α, IL-8, and IL-6.1 Additionally, patients with cyclosporine-induced gingival hyperplasia have increased bacterial colonization with species such as Porphyromonas gingivalis.4 Risk factors for cyclosporine- induced gingival hyperplasia include higher serum concentrations (>400 ng/mL) of cyclosporine, history of gingival hyperplasia, concomitant use of calcium channel blockers, and insufficient oral hygiene.2,3 A study by Seymour and Smith5 found that proper oral hygiene leads to less severe cases of cyclosporine-induced gingival hyperplasia but does not prevent gingival overgrowth. Treatment of cyclosporine-induced gingival hyperplasia traditionally involves targeting oral bacteria and reducing inflammation. Decreasing dental plaque through regular tooth-brushing and interdental cleaning may reduce symptoms such as bleeding and discomfort of the gums.

The intensity of cyclosporine-induced gingival hyperplasia can be reduced with chlorhexidine or azithromycin. Individually, each therapy has been shown to clinically improve cyclosporine-induced gingival hyperplasia; however, to our knowledge the combination of these treatments has not been reported.1 We present a simplified approach to treating cyclosporine-induced gingival hyperplasia using both azithromycin and chlorhexidine. This conservative approach results in effective and sustained improvement of gingival hyperplasia while allowing patients to continue cyclosporine therapy to control underlying disease with minimal adverse effects.

Technique

Before initiating treatment, it is important to confirm that the etiology of gingival hyperplasia is due to cyclosporine use and rule out nutritional deficiencies and autoimmune conditions as potential causes. Be sure to inquire about nutritional intake, systemic symptoms, and family history of autoimmune conditions. Our approach includes the use of azithromycin 500 mg once daily for 7 days followed by chlorhexidine 0.12% oral solution 15 mL twice daily (swish undiluted for 30 seconds, then spit) for at least 3 months for optimal management of gingival hyperplasia. Chlorhexidine should be continued for at least 6 months to maintain symptom resolution. While cyclosporine therapy may be continued throughout the duration of this regimen, consider switching to other immunosuppressive medications that are not associated with gingival hyperplasia (eg, tacrolimus) if symptoms are severe and/or resistant to therapy.1,6

We applied this technique to treat cyclosporine-induced gingival hyperplasia in a 28-year-old woman with a 3-year history of primary aplastic anemia. The patient initially presented with pain and bleeding of the gums of several months’ duration and reported experiencing gum pain when eating solid foods. Her medications included cyclosporine 225 mg daily for aplastic anemia and dapsone 100 mg daily for pneumocystis pneumonia prophylaxis, both of which were taken for the past 6 months. Oral examination revealed pink to bright red hyperplastic gingivae (Figure). She had no other symptoms associated with aplastic anemia and no signs of vitamin or nutritional deficiencies. She denied pre-existing periodontitis prior to starting cyclosporine and reported that the symptoms started several months after initiating cyclosporine therapy. Thus, the clinical diagnosis of cyclosporine-induced gingival hyperplasia was made, and treatment with azithromycin and chlorhexidine was initiated with marked reduction in symptoms.

A, Red and hyperplastic interdental gingiva in a patient with cyclosporine-induced gingival hyperplasia. B, The gingiva showed improvement after 3 months of treatment with azithromycin and chlorhexidine.

Conservative management of gingival hyperplasia with oral hygiene including regular tooth-brushing and flossing and antimicrobial therapies was preferred in this patient to reduce gum pain and minimize the risk for tooth loss while also limiting the use of surgically invasive interventions. Due to limited therapeutic options for aplastic anemia, continued administration of cyclosporine was necessary in our patient to prevent further complications.

Practice Implications

The precise mechanism by which azithromycin treats gingival hyperplasia is unclear but may involve its antimicrobial and anti-inflammatory properties. Small concentrations of azithromycin have been shown to persist in macrophages and fibroblasts of the gingiva even with short-term administration of 3 to 5 days.7 Chlorhexidine is another antimicrobial agent often used in oral rinse solutions to decrease plaque formation and prevent gingivitis. Chlorhexidine can reduce cyclosporine-induced gingival overgrowth when used twice daily.8 After rinsing with chlorhexidine, saliva exhibits antibacterial activity for up to 5 hours; however, tooth and gum discoloration may occur.8

Recurrence of gingival hyperplasia is likely if cyclosporine is not discontinued or maintained with treatment.3 Conventional gingivectomy should be considered for cases in which conservative treatment is ineffective, aesthetic concerns arise, or gingival hyperplasia persists for more than 6 to 12 months after discontinuing cyclosporine.1

We theorize that the microbial properties of azithromycin and chlorhexidine help reduce periodontal inflammation and bacterial overgrowth in patients with cyclosporine-induced gingival hyperplasia, which allows for restoration of gingival health. Our case highlights the efficacy of our treatment approach using a 7-day course of azithromycin followed by twice-daily use of chlorhexidine oral rinse in the treatment of cyclosporine-induced gingival hyperplasia with continued use of cyclosporine.

Cyclosporine is a calcineurin inhibitor and immunosuppressive medication with several indications, including prevention of parenchymal organ and bone marrow transplant rejection as well as treatment of numerous dermatologic conditions (eg, psoriasis, atopic dermatitis). Although it is an effective medication, there are many known adverse effects including nephrotoxicity, hypertension, and gingival hyperplasia.1 Addressing symptomatic cyclosporine-induced gingival hyperplasia can be challenging, especially if continued use of cyclosporine is necessary for adequate control of the underlying disease. We present a simplified approach for conservative management of cyclosporine-induced gingival hyperplasia that allows for continued use of cyclosporine.

Practice Gap

Cyclosporine-induced gingival hyperplasia is a fibrous overgrowth of the interdental papilla and labial gingiva that may lead to gum pain, difficulty eating, gingivitis, and/ or tooth decay or loss.2 The condition usually occurs 3 to 6 months after starting cyclosporine but may occur as soon as 1 month later.1,3 The pathophysiology of this adverse effect is incompletely understood, but several mechanisms have been implicated, including upregulation of the salivary proinflammatory cytokines IL-1α, IL-8, and IL-6.1 Additionally, patients with cyclosporine-induced gingival hyperplasia have increased bacterial colonization with species such as Porphyromonas gingivalis.4 Risk factors for cyclosporine- induced gingival hyperplasia include higher serum concentrations (>400 ng/mL) of cyclosporine, history of gingival hyperplasia, concomitant use of calcium channel blockers, and insufficient oral hygiene.2,3 A study by Seymour and Smith5 found that proper oral hygiene leads to less severe cases of cyclosporine-induced gingival hyperplasia but does not prevent gingival overgrowth. Treatment of cyclosporine-induced gingival hyperplasia traditionally involves targeting oral bacteria and reducing inflammation. Decreasing dental plaque through regular tooth-brushing and interdental cleaning may reduce symptoms such as bleeding and discomfort of the gums.

The intensity of cyclosporine-induced gingival hyperplasia can be reduced with chlorhexidine or azithromycin. Individually, each therapy has been shown to clinically improve cyclosporine-induced gingival hyperplasia; however, to our knowledge the combination of these treatments has not been reported.1 We present a simplified approach to treating cyclosporine-induced gingival hyperplasia using both azithromycin and chlorhexidine. This conservative approach results in effective and sustained improvement of gingival hyperplasia while allowing patients to continue cyclosporine therapy to control underlying disease with minimal adverse effects.

Technique

Before initiating treatment, it is important to confirm that the etiology of gingival hyperplasia is due to cyclosporine use and rule out nutritional deficiencies and autoimmune conditions as potential causes. Be sure to inquire about nutritional intake, systemic symptoms, and family history of autoimmune conditions. Our approach includes the use of azithromycin 500 mg once daily for 7 days followed by chlorhexidine 0.12% oral solution 15 mL twice daily (swish undiluted for 30 seconds, then spit) for at least 3 months for optimal management of gingival hyperplasia. Chlorhexidine should be continued for at least 6 months to maintain symptom resolution. While cyclosporine therapy may be continued throughout the duration of this regimen, consider switching to other immunosuppressive medications that are not associated with gingival hyperplasia (eg, tacrolimus) if symptoms are severe and/or resistant to therapy.1,6

We applied this technique to treat cyclosporine-induced gingival hyperplasia in a 28-year-old woman with a 3-year history of primary aplastic anemia. The patient initially presented with pain and bleeding of the gums of several months’ duration and reported experiencing gum pain when eating solid foods. Her medications included cyclosporine 225 mg daily for aplastic anemia and dapsone 100 mg daily for pneumocystis pneumonia prophylaxis, both of which were taken for the past 6 months. Oral examination revealed pink to bright red hyperplastic gingivae (Figure). She had no other symptoms associated with aplastic anemia and no signs of vitamin or nutritional deficiencies. She denied pre-existing periodontitis prior to starting cyclosporine and reported that the symptoms started several months after initiating cyclosporine therapy. Thus, the clinical diagnosis of cyclosporine-induced gingival hyperplasia was made, and treatment with azithromycin and chlorhexidine was initiated with marked reduction in symptoms.

A, Red and hyperplastic interdental gingiva in a patient with cyclosporine-induced gingival hyperplasia. B, The gingiva showed improvement after 3 months of treatment with azithromycin and chlorhexidine.

Conservative management of gingival hyperplasia with oral hygiene including regular tooth-brushing and flossing and antimicrobial therapies was preferred in this patient to reduce gum pain and minimize the risk for tooth loss while also limiting the use of surgically invasive interventions. Due to limited therapeutic options for aplastic anemia, continued administration of cyclosporine was necessary in our patient to prevent further complications.

Practice Implications

The precise mechanism by which azithromycin treats gingival hyperplasia is unclear but may involve its antimicrobial and anti-inflammatory properties. Small concentrations of azithromycin have been shown to persist in macrophages and fibroblasts of the gingiva even with short-term administration of 3 to 5 days.7 Chlorhexidine is another antimicrobial agent often used in oral rinse solutions to decrease plaque formation and prevent gingivitis. Chlorhexidine can reduce cyclosporine-induced gingival overgrowth when used twice daily.8 After rinsing with chlorhexidine, saliva exhibits antibacterial activity for up to 5 hours; however, tooth and gum discoloration may occur.8

Recurrence of gingival hyperplasia is likely if cyclosporine is not discontinued or maintained with treatment.3 Conventional gingivectomy should be considered for cases in which conservative treatment is ineffective, aesthetic concerns arise, or gingival hyperplasia persists for more than 6 to 12 months after discontinuing cyclosporine.1

We theorize that the microbial properties of azithromycin and chlorhexidine help reduce periodontal inflammation and bacterial overgrowth in patients with cyclosporine-induced gingival hyperplasia, which allows for restoration of gingival health. Our case highlights the efficacy of our treatment approach using a 7-day course of azithromycin followed by twice-daily use of chlorhexidine oral rinse in the treatment of cyclosporine-induced gingival hyperplasia with continued use of cyclosporine.

References
  1. Chojnacka-Purpurowicz J, Wygonowska E, Placek W, et al. Cyclosporine-induced gingival overgrowth—review. Dermatol Ther. 2022;35:E15912.
  2. Greenburg KV, Armitage GC, Shiboski CH. Gingival enlargement among renal transplant recipients in the era of new-generation immunosuppressants. J Periodontol. 2008;79:453-460.
  3. Cyclosporine (ciclosporin)(systemic): drug information. UpToDate. Accessed December 19, 2023. https://www.uptodate.com/contents/table-of-contents/drug-information/general-drug-information
  4. Gong Y, Bi W, Cao L, et al. Association of CD14-260 polymorphisms, red-complex periodontopathogens and gingival crevicular fluid cytokine levels with cyclosporine A-induced gingival overgrowth in renal transplant patients. J Periodontal Res. 2013;48:203-212.
  5. Seymour RA, Smith DG. The effect of a plaque control programme on the incidence and severity of cyclosporin-induced gingival changes. J Clin Periodontol. 1991;18:107-110.
  6. Nash MM, Zaltzman JS. Efficacy of azithromycin in the treatment of cyclosporine-induced gingival hyperplasia in renal transplant recipients. Transplantation. 1998;65:1611-1615.
  7. Martín JM, Mateo E, Jordá E. Utilidad de la azitromicina en la hyperplasia gingival inducida por ciclosporina [azithromycin for the treatment of ciclosporin-induced gingival hyperplasia]. Actas Dermosifiliogr. 2016;107:780.
  8. Gau CH, Tu HS, Chin YT, et al. Can chlorhexidine mouthwash twice daily ameliorate cyclosporine-induced gingival overgrowth? J Formos Med Assoc. 2013;112:131-137.
References
  1. Chojnacka-Purpurowicz J, Wygonowska E, Placek W, et al. Cyclosporine-induced gingival overgrowth—review. Dermatol Ther. 2022;35:E15912.
  2. Greenburg KV, Armitage GC, Shiboski CH. Gingival enlargement among renal transplant recipients in the era of new-generation immunosuppressants. J Periodontol. 2008;79:453-460.
  3. Cyclosporine (ciclosporin)(systemic): drug information. UpToDate. Accessed December 19, 2023. https://www.uptodate.com/contents/table-of-contents/drug-information/general-drug-information
  4. Gong Y, Bi W, Cao L, et al. Association of CD14-260 polymorphisms, red-complex periodontopathogens and gingival crevicular fluid cytokine levels with cyclosporine A-induced gingival overgrowth in renal transplant patients. J Periodontal Res. 2013;48:203-212.
  5. Seymour RA, Smith DG. The effect of a plaque control programme on the incidence and severity of cyclosporin-induced gingival changes. J Clin Periodontol. 1991;18:107-110.
  6. Nash MM, Zaltzman JS. Efficacy of azithromycin in the treatment of cyclosporine-induced gingival hyperplasia in renal transplant recipients. Transplantation. 1998;65:1611-1615.
  7. Martín JM, Mateo E, Jordá E. Utilidad de la azitromicina en la hyperplasia gingival inducida por ciclosporina [azithromycin for the treatment of ciclosporin-induced gingival hyperplasia]. Actas Dermosifiliogr. 2016;107:780.
  8. Gau CH, Tu HS, Chin YT, et al. Can chlorhexidine mouthwash twice daily ameliorate cyclosporine-induced gingival overgrowth? J Formos Med Assoc. 2013;112:131-137.
Issue
Cutis - 114(6)
Issue
Cutis - 114(6)
Page Number
188-189
Page Number
188-189
Publications
Publications
Topics
Article Type
Display Headline

Conservative Approach to Treatment of Cyclosporine-Induced Gingival Hyperplasia With Azithromycin and Chlorhexidine

Display Headline

Conservative Approach to Treatment of Cyclosporine-Induced Gingival Hyperplasia With Azithromycin and Chlorhexidine

Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Gate On Date
Un-Gate On Date
Use ProPublica
CFC Schedule Remove Status
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article
survey writer start date
Article PDF Media

Pinto Bean Pressure Wraps: A Novel Approach to Treating Digital Warts

Article Type
Changed
Display Headline
Pinto Bean Pressure Wraps: A Novel Approach to Treating Digital Warts

Practice Gap

Verruca vulgaris is a common dermatologic challenge due to its high prevalence and tendency to recur following routinely employed destructive modalities (eg, cryotherapy, electrosurgery), which can incur a considerable amount of pain and some risk for scarring.1,2 Other treatment methods for warts such as topical salicylic acid preparations, topical immunotherapy, or intralesional allergen injections often require multiple treatment sessions.3,4 Furthermore, the financial burden of traditional wart treatment can be substantial.4 Better techniques are needed to improve the clinician’s approach to treating warts. We describe a home-based technique to treat common digital warts using pinto bean pressure wraps to induce ischemic changes in wart tissue with similar response rates to commonly used modalities.

Technique

Our technique utilizes a small, hard, convex object that is applied directly over the digital wart. A simple self-adhesive wrap is used to cover the object and maintain constant pressure on the wart overnight. We typically use a dried pinto bean (a variety of the common bean Phaseolus vulgaris) acquired from a local grocery store due to its ideal size, hard surface, and convex shape (Figure 1). The bean is taped in place directly overlying the wart and covered with a self-adhesive wrap overnight. The wrap is removed in the morning, and often no further treatment is needed. The ischemic wart tissue is allowed to slough spontaneously over 1 to 2 weeks. No wound care or dressing is necessary (Figure 2). Larger warts may require application of the pressure wraps for 2 to 3 additional nights. While most warts resolve with this technique, we have observed a recurrence rate similar to that for cryotherapy. Patients are advised that any recurrent warts can be re-treated monthly, if needed, until resolution.

FIGURE 1. A, The home pressure wrap kit includes pinto beans, stretch tape, and a self-adherent wrap. B, A pinto bean is taped in place directly over the wart. C, The selfadherent wrap is applied to augment the pressure of the secured bean.

FIGURE 2. A–C, The digital wart before treatment, 2 days after a single overnight pressure wrap application showing necrosis of the wart, and 6 days posttreatment showing evidence of sloughing.

What to Use and How to Prepare—Any small, hard, convex object can be used for the pressure wrap; we also have used appropriately sized and shaped plastic shirt buttons with similar results. Home kits can be assembled in advance and provided to patients at their initial visit along with appropriate instructions (Figure 1A).

Effects on the Skin and Distal Digit—Application of pressure wraps does not harm normal skin; however, care should be taken when the self-adherent wrap is applied so as not to induce ischemia of the distal digit. The wrap should be applied using gentle pressure with patients experiencing minimal discomfort from the overnight application.

Indications—This pressure wrap technique can be employed on most digital warts, including periungual warts, which can be difficult to treat by other means. However, in our experience this technique is not effective for nondigital warts, likely due to the inability to maintain adequate pressure with the overlying dressing. Patients at risk for compromised digital perfusion, such as those with Raynaud phenomenon or systemic sclerosis, should not be treated with pressure wraps due to possible digital ischemia.

Precautions—Patients should be advised that the pinto bean should only be used if dry and should not be ingested. The bean can be a choking hazard for small children, therefore appropriate precautions should be used. Allergic contact dermatitis to the materials used in this technique is possible, but we have never observed this. The pinto bean can be reused for future application as long as it remains dry and provides a hard convex surface.

Practice Implications

The probable mechanism of the ischemic changes to the wart tissue likely is the occlusion of tortuous blood vessels in the dermal papillae, which are intrinsic to wart tissue and absent in normal skin.1 This pressure-induced ischemic injury allows for selective destruction of the wart tissue with sparing of the normal skin. Our technique is fairly novel, although at least one report in the literature has described the use of a mechanical device to induce ischemic changes in skin tags.5

The use of pinto bean pressure wraps to induce ischemic change in digital warts provides a low-risk and nearly pain-free alternative to more expensive and invasive treatment methods. Moreover, this technique allows for a low-cost home-based therapy that can be repeated easily for other digital sites or if recurrence is noted.

References
  1. Cardoso J, Calonje E. Cutaneous manifestations of human papillomaviruses: a review. Acta Dermatovenerol Alp Pannonica Adriat. 2011;20:145-154. 
  2. Lipke M. An armamentarium of wart treatments. Clin Med Res. 2006;4:273-293. doi:10.3121/cmr.4.4.273 
  3. Muse M, Stiff K, Glines K, et al. A review of intralesional wart therapy. Dermatol Online J. 2020;26:2. doi:10.5070/D3263048027
  4. Berna R, Margolis D, Barbieri J. Annual health care utilization and costs for treatment of cutaneous and anogenital warts among a commercially insured population in the US, 2017-2019. JAMA Dermatol. 2022;158:695-697. doi:10.1001/jamadermatol.2022.0964
  5. Fredriksson C, Ilias M, Anderson C. New mechanical device for effective removal of skin tags in routine health care. Dermatol Online J. 2009;15:9. doi:10.5070/D37tj2800k
Article PDF
Author and Disclosure Information

From Forefront Dermatology, West Burlington, Iowa.

The authors have no relevant financial disclosures to report.

Correspondence: Mark G. Cleveland, MD, PhD, 1225 S Gear Ave, Ste 252, West Burlington, IA 52655 ([email protected]).

Cutis. 2024 November;114(5):169-170. doi:10.12788/cutis.1121

Issue
Cutis - 114(5)
Publications
Topics
Page Number
169-170
Sections
Author and Disclosure Information

From Forefront Dermatology, West Burlington, Iowa.

The authors have no relevant financial disclosures to report.

Correspondence: Mark G. Cleveland, MD, PhD, 1225 S Gear Ave, Ste 252, West Burlington, IA 52655 ([email protected]).

Cutis. 2024 November;114(5):169-170. doi:10.12788/cutis.1121

Author and Disclosure Information

From Forefront Dermatology, West Burlington, Iowa.

The authors have no relevant financial disclosures to report.

Correspondence: Mark G. Cleveland, MD, PhD, 1225 S Gear Ave, Ste 252, West Burlington, IA 52655 ([email protected]).

Cutis. 2024 November;114(5):169-170. doi:10.12788/cutis.1121

Article PDF
Article PDF

Practice Gap

Verruca vulgaris is a common dermatologic challenge due to its high prevalence and tendency to recur following routinely employed destructive modalities (eg, cryotherapy, electrosurgery), which can incur a considerable amount of pain and some risk for scarring.1,2 Other treatment methods for warts such as topical salicylic acid preparations, topical immunotherapy, or intralesional allergen injections often require multiple treatment sessions.3,4 Furthermore, the financial burden of traditional wart treatment can be substantial.4 Better techniques are needed to improve the clinician’s approach to treating warts. We describe a home-based technique to treat common digital warts using pinto bean pressure wraps to induce ischemic changes in wart tissue with similar response rates to commonly used modalities.

Technique

Our technique utilizes a small, hard, convex object that is applied directly over the digital wart. A simple self-adhesive wrap is used to cover the object and maintain constant pressure on the wart overnight. We typically use a dried pinto bean (a variety of the common bean Phaseolus vulgaris) acquired from a local grocery store due to its ideal size, hard surface, and convex shape (Figure 1). The bean is taped in place directly overlying the wart and covered with a self-adhesive wrap overnight. The wrap is removed in the morning, and often no further treatment is needed. The ischemic wart tissue is allowed to slough spontaneously over 1 to 2 weeks. No wound care or dressing is necessary (Figure 2). Larger warts may require application of the pressure wraps for 2 to 3 additional nights. While most warts resolve with this technique, we have observed a recurrence rate similar to that for cryotherapy. Patients are advised that any recurrent warts can be re-treated monthly, if needed, until resolution.

FIGURE 1. A, The home pressure wrap kit includes pinto beans, stretch tape, and a self-adherent wrap. B, A pinto bean is taped in place directly over the wart. C, The selfadherent wrap is applied to augment the pressure of the secured bean.

FIGURE 2. A–C, The digital wart before treatment, 2 days after a single overnight pressure wrap application showing necrosis of the wart, and 6 days posttreatment showing evidence of sloughing.

What to Use and How to Prepare—Any small, hard, convex object can be used for the pressure wrap; we also have used appropriately sized and shaped plastic shirt buttons with similar results. Home kits can be assembled in advance and provided to patients at their initial visit along with appropriate instructions (Figure 1A).

Effects on the Skin and Distal Digit—Application of pressure wraps does not harm normal skin; however, care should be taken when the self-adherent wrap is applied so as not to induce ischemia of the distal digit. The wrap should be applied using gentle pressure with patients experiencing minimal discomfort from the overnight application.

Indications—This pressure wrap technique can be employed on most digital warts, including periungual warts, which can be difficult to treat by other means. However, in our experience this technique is not effective for nondigital warts, likely due to the inability to maintain adequate pressure with the overlying dressing. Patients at risk for compromised digital perfusion, such as those with Raynaud phenomenon or systemic sclerosis, should not be treated with pressure wraps due to possible digital ischemia.

Precautions—Patients should be advised that the pinto bean should only be used if dry and should not be ingested. The bean can be a choking hazard for small children, therefore appropriate precautions should be used. Allergic contact dermatitis to the materials used in this technique is possible, but we have never observed this. The pinto bean can be reused for future application as long as it remains dry and provides a hard convex surface.

Practice Implications

The probable mechanism of the ischemic changes to the wart tissue likely is the occlusion of tortuous blood vessels in the dermal papillae, which are intrinsic to wart tissue and absent in normal skin.1 This pressure-induced ischemic injury allows for selective destruction of the wart tissue with sparing of the normal skin. Our technique is fairly novel, although at least one report in the literature has described the use of a mechanical device to induce ischemic changes in skin tags.5

The use of pinto bean pressure wraps to induce ischemic change in digital warts provides a low-risk and nearly pain-free alternative to more expensive and invasive treatment methods. Moreover, this technique allows for a low-cost home-based therapy that can be repeated easily for other digital sites or if recurrence is noted.

Practice Gap

Verruca vulgaris is a common dermatologic challenge due to its high prevalence and tendency to recur following routinely employed destructive modalities (eg, cryotherapy, electrosurgery), which can incur a considerable amount of pain and some risk for scarring.1,2 Other treatment methods for warts such as topical salicylic acid preparations, topical immunotherapy, or intralesional allergen injections often require multiple treatment sessions.3,4 Furthermore, the financial burden of traditional wart treatment can be substantial.4 Better techniques are needed to improve the clinician’s approach to treating warts. We describe a home-based technique to treat common digital warts using pinto bean pressure wraps to induce ischemic changes in wart tissue with similar response rates to commonly used modalities.

Technique

Our technique utilizes a small, hard, convex object that is applied directly over the digital wart. A simple self-adhesive wrap is used to cover the object and maintain constant pressure on the wart overnight. We typically use a dried pinto bean (a variety of the common bean Phaseolus vulgaris) acquired from a local grocery store due to its ideal size, hard surface, and convex shape (Figure 1). The bean is taped in place directly overlying the wart and covered with a self-adhesive wrap overnight. The wrap is removed in the morning, and often no further treatment is needed. The ischemic wart tissue is allowed to slough spontaneously over 1 to 2 weeks. No wound care or dressing is necessary (Figure 2). Larger warts may require application of the pressure wraps for 2 to 3 additional nights. While most warts resolve with this technique, we have observed a recurrence rate similar to that for cryotherapy. Patients are advised that any recurrent warts can be re-treated monthly, if needed, until resolution.

FIGURE 1. A, The home pressure wrap kit includes pinto beans, stretch tape, and a self-adherent wrap. B, A pinto bean is taped in place directly over the wart. C, The selfadherent wrap is applied to augment the pressure of the secured bean.

FIGURE 2. A–C, The digital wart before treatment, 2 days after a single overnight pressure wrap application showing necrosis of the wart, and 6 days posttreatment showing evidence of sloughing.

What to Use and How to Prepare—Any small, hard, convex object can be used for the pressure wrap; we also have used appropriately sized and shaped plastic shirt buttons with similar results. Home kits can be assembled in advance and provided to patients at their initial visit along with appropriate instructions (Figure 1A).

Effects on the Skin and Distal Digit—Application of pressure wraps does not harm normal skin; however, care should be taken when the self-adherent wrap is applied so as not to induce ischemia of the distal digit. The wrap should be applied using gentle pressure with patients experiencing minimal discomfort from the overnight application.

Indications—This pressure wrap technique can be employed on most digital warts, including periungual warts, which can be difficult to treat by other means. However, in our experience this technique is not effective for nondigital warts, likely due to the inability to maintain adequate pressure with the overlying dressing. Patients at risk for compromised digital perfusion, such as those with Raynaud phenomenon or systemic sclerosis, should not be treated with pressure wraps due to possible digital ischemia.

Precautions—Patients should be advised that the pinto bean should only be used if dry and should not be ingested. The bean can be a choking hazard for small children, therefore appropriate precautions should be used. Allergic contact dermatitis to the materials used in this technique is possible, but we have never observed this. The pinto bean can be reused for future application as long as it remains dry and provides a hard convex surface.

Practice Implications

The probable mechanism of the ischemic changes to the wart tissue likely is the occlusion of tortuous blood vessels in the dermal papillae, which are intrinsic to wart tissue and absent in normal skin.1 This pressure-induced ischemic injury allows for selective destruction of the wart tissue with sparing of the normal skin. Our technique is fairly novel, although at least one report in the literature has described the use of a mechanical device to induce ischemic changes in skin tags.5

The use of pinto bean pressure wraps to induce ischemic change in digital warts provides a low-risk and nearly pain-free alternative to more expensive and invasive treatment methods. Moreover, this technique allows for a low-cost home-based therapy that can be repeated easily for other digital sites or if recurrence is noted.

References
  1. Cardoso J, Calonje E. Cutaneous manifestations of human papillomaviruses: a review. Acta Dermatovenerol Alp Pannonica Adriat. 2011;20:145-154. 
  2. Lipke M. An armamentarium of wart treatments. Clin Med Res. 2006;4:273-293. doi:10.3121/cmr.4.4.273 
  3. Muse M, Stiff K, Glines K, et al. A review of intralesional wart therapy. Dermatol Online J. 2020;26:2. doi:10.5070/D3263048027
  4. Berna R, Margolis D, Barbieri J. Annual health care utilization and costs for treatment of cutaneous and anogenital warts among a commercially insured population in the US, 2017-2019. JAMA Dermatol. 2022;158:695-697. doi:10.1001/jamadermatol.2022.0964
  5. Fredriksson C, Ilias M, Anderson C. New mechanical device for effective removal of skin tags in routine health care. Dermatol Online J. 2009;15:9. doi:10.5070/D37tj2800k
References
  1. Cardoso J, Calonje E. Cutaneous manifestations of human papillomaviruses: a review. Acta Dermatovenerol Alp Pannonica Adriat. 2011;20:145-154. 
  2. Lipke M. An armamentarium of wart treatments. Clin Med Res. 2006;4:273-293. doi:10.3121/cmr.4.4.273 
  3. Muse M, Stiff K, Glines K, et al. A review of intralesional wart therapy. Dermatol Online J. 2020;26:2. doi:10.5070/D3263048027
  4. Berna R, Margolis D, Barbieri J. Annual health care utilization and costs for treatment of cutaneous and anogenital warts among a commercially insured population in the US, 2017-2019. JAMA Dermatol. 2022;158:695-697. doi:10.1001/jamadermatol.2022.0964
  5. Fredriksson C, Ilias M, Anderson C. New mechanical device for effective removal of skin tags in routine health care. Dermatol Online J. 2009;15:9. doi:10.5070/D37tj2800k
Issue
Cutis - 114(5)
Issue
Cutis - 114(5)
Page Number
169-170
Page Number
169-170
Publications
Publications
Topics
Article Type
Display Headline
Pinto Bean Pressure Wraps: A Novel Approach to Treating Digital Warts
Display Headline
Pinto Bean Pressure Wraps: A Novel Approach to Treating Digital Warts
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Use ProPublica
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article
Article PDF Media

Nailing the Nail Biopsy: Surgical Instruments and Their Function in Nail Biopsy Procedures

Article Type
Changed

Practice Gap

The term nail biopsy (NB) may refer to a punch, excisional, shave, or longitudinal biopsy of the nail matrix and/or nail bed.1 Nail surgeries, including NBs, are performed relatively infrequently. In a study using data from the Medicare Provider Utilization and Payment Database 2012-2017, only 1.01% of Mohs surgeons and 0.28% of general dermatologists in the United States performed NBs. Thirty-one states had no dermatologist-performed NBs, while 3 states had no nail biopsies performed by any physician, podiatrist, nurse practitioner, or physician assistant, indicating that there is a shortage of dermatology clinicians performing nail surgeries.2

Dermatologists may not be performing NBs due to unfamiliarity with nail unit anatomy and lack of formal NB training during residency.3 In a survey of 240 dermatology residents in the United States, 58% reported performing fewer than 10 nail procedures during residency, with 25% observing only.4 Of those surveyed, 1% had no exposure to nail procedures during 3 years of residency. Furthermore, when asked to assess their competency in nail surgery on a scale of not competent, competent, and very competent, approximately 30% responded that they were not competent.4 Without sufficient education on procedures involving the nail unit, residents may be reluctant to incorporate nail surgery into their clinical practice.

Due to their complexity, NBs require the use of several specialized surgical instruments that are not used for other dermatologic procedures, and residents and attending physicians who have limited nail training may be unfamiliar with these tools. To address this educational gap, we sought to create a guide that details the surgical instruments used for the nail matrix tangential excision (shave) biopsy technique—the most common technique used in our nail specialty clinic. This guide is intended for educational use by dermatologists who wish to incorporate NB as part of their practice.

Tools and Technique

As a major referral center, our New York City–based nail specialty clinic performs a large volume of NBs, many of them performed for clinically concerning longitudinal melanonychias for which a nail matrix shave biopsy most often is performed. We utilize a standardized tray consisting of 12 surgical instruments that are needed to successfully perform a NB from start to finish (Figure). In addition to standard surgical tray items, such as sutures and tissue scissors, additional specialized instruments are necessary for NB procedures, including a nail elevator, an English nail splitter, and skin hook.

Surgical instruments utilized during a nail biopsy procedure: 1, #15 Teflon-coated surgical blade; 2, needle driver; 3, forceps with teeth; 4, scalpel handle; 5, Mayo scissors; 6, nail elevator; 7, skin hook; 8, clamp; 9, suture scissors; 10, tissue scissors; 11, English nail splitter; 12, absorbable suture polyglactin 910 on a P3 needle.

After the initial incisions are made at 45° angles to the proximal nail fold surrounding the longitudinal band, the nail elevator is used to separate the proximal nail plate from the underlying nail bed. The English nail splitter is used to create a transverse split separating the proximal from the distal nail plate, and the proximal nail plate then is retracted using a clamp. The skin hook is used to retract the proximal nail fold to expose the pigment in the nail matrix, which is biopsied using the #15 blade and sent for histopathology. The proximal nail fold and retracted nail plate then are put back in place, and absorbable sutures are used to repair the defect. In certain cases, a 3-mm punch biopsy may be used to sample the nail plate and/or the surrounding soft tissue.

Practice Implications

A guide to surgical tools used during NB procedures, including less commonly encountered tools such as a nail elevator and English nail splitter, helps to close the educational gap of NB procedures among dermatology trainees and attending physicians. In conjunction with practical training with cadavers and models, a guide to surgical tools can be reviewed by trainees before hands-on exposure to nail surgery in a clinical setting. By increasing awareness of the tools needed to complete the procedure from start to finish, dermatologists may feel more prepared and confident in their ability to perform NBs, ultimately allowing for more rapid diagnosis of nail malignancies.

References
  1. Grover C, Bansal S. Nail biopsy: a user’s manual. Indian Dermatol Online J. 2018;9:3-15. doi:10.4103/idoj.IDOJ_268_17
  2. Wang Y, Lipner SR. Retrospective analysis of nail biopsies performed using the Medicare Provider Utilization and Payment Database 2012 to 2017. Dermatol Ther. 2021;34:e14928. doi:10.1111/dth.14928
  3. Hare AQ, Rich P. Clinical and educational gaps in diagnosis of nail disorders. Dermatol Clin. 2016;34:269-273. doi:10.1016/j.det.2016.02.002
  4. Lee EH, Nehal KS, Dusza SW, et al. Procedural dermatology training during dermatology residency: a survey of third-year dermatology residents. J Am Acad Dermatol. 2011;64:475-483.e4835. doi:10.1016/j.jaad.2010.05.044
Article PDF
Author and Disclosure Information

 

Rachel C. Hill is from Weill Cornell Medical College, New York, New York. Apostolos Katsiaunis is from Tufts University School of Medicine, Boston, Massachusetts. Dr. Lipner is from the Department of Dermatology, Weill Cornell Medicine, New York.

Rachel C. Hill and Apostolos Katsiaunis have no relevant financial disclosures to report. Dr. Lipner has served as a consultant for BelleTorus Corporation, Eli Lilly, Moberg Pharmaceuticals, and Ortho-Dermatologics.

Correspondence: Shari R. Lipner MD, PhD, 1305 York Ave, New York, NY 10021 ([email protected]).

Cutis. 2024 October;114(4):128, 130. doi:10.12788/cutis.1104

Issue
Cutis - 114(4)
Publications
Topics
Page Number
128,130
Sections
Author and Disclosure Information

 

Rachel C. Hill is from Weill Cornell Medical College, New York, New York. Apostolos Katsiaunis is from Tufts University School of Medicine, Boston, Massachusetts. Dr. Lipner is from the Department of Dermatology, Weill Cornell Medicine, New York.

Rachel C. Hill and Apostolos Katsiaunis have no relevant financial disclosures to report. Dr. Lipner has served as a consultant for BelleTorus Corporation, Eli Lilly, Moberg Pharmaceuticals, and Ortho-Dermatologics.

Correspondence: Shari R. Lipner MD, PhD, 1305 York Ave, New York, NY 10021 ([email protected]).

Cutis. 2024 October;114(4):128, 130. doi:10.12788/cutis.1104

Author and Disclosure Information

 

Rachel C. Hill is from Weill Cornell Medical College, New York, New York. Apostolos Katsiaunis is from Tufts University School of Medicine, Boston, Massachusetts. Dr. Lipner is from the Department of Dermatology, Weill Cornell Medicine, New York.

Rachel C. Hill and Apostolos Katsiaunis have no relevant financial disclosures to report. Dr. Lipner has served as a consultant for BelleTorus Corporation, Eli Lilly, Moberg Pharmaceuticals, and Ortho-Dermatologics.

Correspondence: Shari R. Lipner MD, PhD, 1305 York Ave, New York, NY 10021 ([email protected]).

Cutis. 2024 October;114(4):128, 130. doi:10.12788/cutis.1104

Article PDF
Article PDF

Practice Gap

The term nail biopsy (NB) may refer to a punch, excisional, shave, or longitudinal biopsy of the nail matrix and/or nail bed.1 Nail surgeries, including NBs, are performed relatively infrequently. In a study using data from the Medicare Provider Utilization and Payment Database 2012-2017, only 1.01% of Mohs surgeons and 0.28% of general dermatologists in the United States performed NBs. Thirty-one states had no dermatologist-performed NBs, while 3 states had no nail biopsies performed by any physician, podiatrist, nurse practitioner, or physician assistant, indicating that there is a shortage of dermatology clinicians performing nail surgeries.2

Dermatologists may not be performing NBs due to unfamiliarity with nail unit anatomy and lack of formal NB training during residency.3 In a survey of 240 dermatology residents in the United States, 58% reported performing fewer than 10 nail procedures during residency, with 25% observing only.4 Of those surveyed, 1% had no exposure to nail procedures during 3 years of residency. Furthermore, when asked to assess their competency in nail surgery on a scale of not competent, competent, and very competent, approximately 30% responded that they were not competent.4 Without sufficient education on procedures involving the nail unit, residents may be reluctant to incorporate nail surgery into their clinical practice.

Due to their complexity, NBs require the use of several specialized surgical instruments that are not used for other dermatologic procedures, and residents and attending physicians who have limited nail training may be unfamiliar with these tools. To address this educational gap, we sought to create a guide that details the surgical instruments used for the nail matrix tangential excision (shave) biopsy technique—the most common technique used in our nail specialty clinic. This guide is intended for educational use by dermatologists who wish to incorporate NB as part of their practice.

Tools and Technique

As a major referral center, our New York City–based nail specialty clinic performs a large volume of NBs, many of them performed for clinically concerning longitudinal melanonychias for which a nail matrix shave biopsy most often is performed. We utilize a standardized tray consisting of 12 surgical instruments that are needed to successfully perform a NB from start to finish (Figure). In addition to standard surgical tray items, such as sutures and tissue scissors, additional specialized instruments are necessary for NB procedures, including a nail elevator, an English nail splitter, and skin hook.

Surgical instruments utilized during a nail biopsy procedure: 1, #15 Teflon-coated surgical blade; 2, needle driver; 3, forceps with teeth; 4, scalpel handle; 5, Mayo scissors; 6, nail elevator; 7, skin hook; 8, clamp; 9, suture scissors; 10, tissue scissors; 11, English nail splitter; 12, absorbable suture polyglactin 910 on a P3 needle.

After the initial incisions are made at 45° angles to the proximal nail fold surrounding the longitudinal band, the nail elevator is used to separate the proximal nail plate from the underlying nail bed. The English nail splitter is used to create a transverse split separating the proximal from the distal nail plate, and the proximal nail plate then is retracted using a clamp. The skin hook is used to retract the proximal nail fold to expose the pigment in the nail matrix, which is biopsied using the #15 blade and sent for histopathology. The proximal nail fold and retracted nail plate then are put back in place, and absorbable sutures are used to repair the defect. In certain cases, a 3-mm punch biopsy may be used to sample the nail plate and/or the surrounding soft tissue.

Practice Implications

A guide to surgical tools used during NB procedures, including less commonly encountered tools such as a nail elevator and English nail splitter, helps to close the educational gap of NB procedures among dermatology trainees and attending physicians. In conjunction with practical training with cadavers and models, a guide to surgical tools can be reviewed by trainees before hands-on exposure to nail surgery in a clinical setting. By increasing awareness of the tools needed to complete the procedure from start to finish, dermatologists may feel more prepared and confident in their ability to perform NBs, ultimately allowing for more rapid diagnosis of nail malignancies.

Practice Gap

The term nail biopsy (NB) may refer to a punch, excisional, shave, or longitudinal biopsy of the nail matrix and/or nail bed.1 Nail surgeries, including NBs, are performed relatively infrequently. In a study using data from the Medicare Provider Utilization and Payment Database 2012-2017, only 1.01% of Mohs surgeons and 0.28% of general dermatologists in the United States performed NBs. Thirty-one states had no dermatologist-performed NBs, while 3 states had no nail biopsies performed by any physician, podiatrist, nurse practitioner, or physician assistant, indicating that there is a shortage of dermatology clinicians performing nail surgeries.2

Dermatologists may not be performing NBs due to unfamiliarity with nail unit anatomy and lack of formal NB training during residency.3 In a survey of 240 dermatology residents in the United States, 58% reported performing fewer than 10 nail procedures during residency, with 25% observing only.4 Of those surveyed, 1% had no exposure to nail procedures during 3 years of residency. Furthermore, when asked to assess their competency in nail surgery on a scale of not competent, competent, and very competent, approximately 30% responded that they were not competent.4 Without sufficient education on procedures involving the nail unit, residents may be reluctant to incorporate nail surgery into their clinical practice.

Due to their complexity, NBs require the use of several specialized surgical instruments that are not used for other dermatologic procedures, and residents and attending physicians who have limited nail training may be unfamiliar with these tools. To address this educational gap, we sought to create a guide that details the surgical instruments used for the nail matrix tangential excision (shave) biopsy technique—the most common technique used in our nail specialty clinic. This guide is intended for educational use by dermatologists who wish to incorporate NB as part of their practice.

Tools and Technique

As a major referral center, our New York City–based nail specialty clinic performs a large volume of NBs, many of them performed for clinically concerning longitudinal melanonychias for which a nail matrix shave biopsy most often is performed. We utilize a standardized tray consisting of 12 surgical instruments that are needed to successfully perform a NB from start to finish (Figure). In addition to standard surgical tray items, such as sutures and tissue scissors, additional specialized instruments are necessary for NB procedures, including a nail elevator, an English nail splitter, and skin hook.

Surgical instruments utilized during a nail biopsy procedure: 1, #15 Teflon-coated surgical blade; 2, needle driver; 3, forceps with teeth; 4, scalpel handle; 5, Mayo scissors; 6, nail elevator; 7, skin hook; 8, clamp; 9, suture scissors; 10, tissue scissors; 11, English nail splitter; 12, absorbable suture polyglactin 910 on a P3 needle.

After the initial incisions are made at 45° angles to the proximal nail fold surrounding the longitudinal band, the nail elevator is used to separate the proximal nail plate from the underlying nail bed. The English nail splitter is used to create a transverse split separating the proximal from the distal nail plate, and the proximal nail plate then is retracted using a clamp. The skin hook is used to retract the proximal nail fold to expose the pigment in the nail matrix, which is biopsied using the #15 blade and sent for histopathology. The proximal nail fold and retracted nail plate then are put back in place, and absorbable sutures are used to repair the defect. In certain cases, a 3-mm punch biopsy may be used to sample the nail plate and/or the surrounding soft tissue.

Practice Implications

A guide to surgical tools used during NB procedures, including less commonly encountered tools such as a nail elevator and English nail splitter, helps to close the educational gap of NB procedures among dermatology trainees and attending physicians. In conjunction with practical training with cadavers and models, a guide to surgical tools can be reviewed by trainees before hands-on exposure to nail surgery in a clinical setting. By increasing awareness of the tools needed to complete the procedure from start to finish, dermatologists may feel more prepared and confident in their ability to perform NBs, ultimately allowing for more rapid diagnosis of nail malignancies.

References
  1. Grover C, Bansal S. Nail biopsy: a user’s manual. Indian Dermatol Online J. 2018;9:3-15. doi:10.4103/idoj.IDOJ_268_17
  2. Wang Y, Lipner SR. Retrospective analysis of nail biopsies performed using the Medicare Provider Utilization and Payment Database 2012 to 2017. Dermatol Ther. 2021;34:e14928. doi:10.1111/dth.14928
  3. Hare AQ, Rich P. Clinical and educational gaps in diagnosis of nail disorders. Dermatol Clin. 2016;34:269-273. doi:10.1016/j.det.2016.02.002
  4. Lee EH, Nehal KS, Dusza SW, et al. Procedural dermatology training during dermatology residency: a survey of third-year dermatology residents. J Am Acad Dermatol. 2011;64:475-483.e4835. doi:10.1016/j.jaad.2010.05.044
References
  1. Grover C, Bansal S. Nail biopsy: a user’s manual. Indian Dermatol Online J. 2018;9:3-15. doi:10.4103/idoj.IDOJ_268_17
  2. Wang Y, Lipner SR. Retrospective analysis of nail biopsies performed using the Medicare Provider Utilization and Payment Database 2012 to 2017. Dermatol Ther. 2021;34:e14928. doi:10.1111/dth.14928
  3. Hare AQ, Rich P. Clinical and educational gaps in diagnosis of nail disorders. Dermatol Clin. 2016;34:269-273. doi:10.1016/j.det.2016.02.002
  4. Lee EH, Nehal KS, Dusza SW, et al. Procedural dermatology training during dermatology residency: a survey of third-year dermatology residents. J Am Acad Dermatol. 2011;64:475-483.e4835. doi:10.1016/j.jaad.2010.05.044
Issue
Cutis - 114(4)
Issue
Cutis - 114(4)
Page Number
128,130
Page Number
128,130
Publications
Publications
Topics
Article Type
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Use ProPublica
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article
Article PDF Media

Enhanced Care for Pediatric Patients With Generalized Lichen Planus: Diagnosis and Treatment Tips

Article Type
Changed
Display Headline
Enhanced Care for Pediatric Patients With Generalized Lichen Planus: Diagnosis and Treatment Tips

Practice Gap

Lichen planus (LP) is an inflammatory cutaneous disorder. Although it often is characterized by the 6 Ps—pruritic, polygonal, planar, purple, papules, and plaques with a predilection for the wrists and ankles—the presentation can vary in morphology and distribution.1-5 With an incidence of approximately 1% in the general population, LP is undoubtedly uncommon.1 Its prevalence in the pediatric population is especially low, with only 2% to 3% of cases manifesting in individuals younger than 20 years.2

Generalized LP (also referred to as eruptive or exanthematous LP) is a rarely reported clinical subtype in which lesions are disseminated or spread rapidly.5 The rarity of generalized LP in children often leads to misdiagnosis or delayed treatment, impacting the patient’s quality of life. Thus, there is a need for heightened awareness among clinicians on the variable presentation of LP in the pediatric population. Incorporating a punch biopsy for the diagnosis of LP when lesions manifest as widespread, erythematous to violaceous, flat-topped papules or plaques, along with the addition of an intramuscular (IM) injection in the treatment plan, improves overall patient outcomes.

Tools and Techniques

A detailed physical examination followed by a punch biopsy was critical for the diagnosis of generalized LP in a 7-year-old Black girl. The examination revealed a widespread distribution of dark, violaceous, polygonal, shiny, flat-topped, firm papules coalescing into plaques across the entire body, with a greater predilection for the legs and overlying joints (Figure, A). Some lesions exhibited fine, silver-white, reticular patterns consistent with Wickham striae. Notably, there was no involvement of the scalp, nails, or mucosal surfaces.

A, Diffuse, dark, violaceous, polygonal, shiny, flat-topped, firm papules coalescing into plaques on the legs and overlying the joints in a 7-year-old girl with generalized lichen planus. B, Combination therapy with clobetasol cream 0.025% and 0.5 cc of intramuscular triamcinolone 40 mg/mL resulted in improvement of lesions and residual hyperpigmentation at 2-week follow-up.

The patient had no relevant medical or family history of skin disease and no recent history of illness. She previously was treated by a pediatrician with triamcinolone cream 0.1%, a course of oral cephalexin, and oral cetirizine 10 mg once daily without relief of symptoms.

Although the clinical presentation was consistent with LP, the differential diagnosis included lichen simplex chronicus, atopic dermatitis, psoriasis, and generalized granuloma annulare. To address the need for early recognition of LP in pediatric patients, a punch biopsy of a lesion on the left anterior thigh was performed and showed lichenoid interface dermatitis—a pivotal finding in distinguishing LP from other conditions in the differential.

Given the patient’s age and severity of the LP, a combination of topical and systemic therapies was prescribed—clobetasol cream 0.025% twice daily and 1 injection of 0.5 cc of IM triamcinolone acetonide 40 mg/mL. This regimen was guided by the efficacy of IM injections in providing prompt symptomatic relief, particularly for patients with extensive disease or for those whose condition is refractory to topical treatments.6 Our patient achieved remarkable improvement at 2-week ­follow-up (Figure, B), without any observed adverse effects. At that time, the patient’s mother refused further systemic treatment and opted for only the topical therapy as well as natural light therapy.

Practice Implications

Timely and accurate diagnosis of LP in pediatric patients, especially those with skin of color, is crucial. Early intervention is especially important in mitigating the risk for chronic symptoms and preventing potential scarring, which tends to be more pronounced and challenging to treat in individuals with darker skin tones.7 Although not present in our patient, it is important to note that LP can affect the face (including the eyelids) as well as the palms and soles in pediatric patients with skin of color.

The most common approach to management of pediatric LP involves the use of a topical corticosteroid and an oral antihistamine, but the recalcitrant and generalized distribution of lesions warrants the administration of a systemic corticosteroid regardless of the patient’s age.6 In our patient, prompt administration of low-dose IM triamcinolone was both crucial and beneficial. Although an underutilized approach, IM triamcinolone helps to prevent the progression of lesions to the scalp, nails, and mucosa while also reducing inflammation and pruritus in glabrous skin.8

Triamcinolone acetonide injections—­administered at concentrations of 5 to 40 mg/mL—directly into the lesion (0.5–1 cc per 2 cm2) are highly effective in managing recalcitrant thickened lesions such as those seen in hypertrophic LP and palmoplantar LP.6 This treatment is particularly beneficial when lesions are unresponsive to topical therapies. Administered every 3 to 6 weeks, these injections provide rapid symptom relief, typically within 72 hours,6 while also contributing to the reduction of lesion size and thickness over time. The concentration of triamcinolone acetonide should be selected based on the lesion’s severity, with higher concentrations reserved for thicker, more resistant lesions. More frequent injections may be warranted in cases in which rapid lesion reduction is necessary, while less frequent sessions may suffice for maintenance therapy. It is important to follow patients closely for adverse effects, such as signs of local skin atrophy or hypopigmentation, and to adjust the dose or frequency accordingly. To mitigate these risks, consider using the lowest effective concentration and rotating injection sites if treating multiple lesions. Additionally, combining intralesional corticosteroids with topical therapies can enhance outcomes, particularly in cases in which monotherapy is insufficient.

Patients should be monitored vigilantly for complications of LP. The risk for postinflammatory hyperpigmentation is a particular concern for patients with skin of color. Other complications of untreated LP include nail deformities and scarring alopecia.9 Regular and thorough follow-ups every few months to monitor scalp, mucosal, and genital involvement are essential to manage this risk effectively.

Furthermore, patient education is key. Informing patients and their caregivers about the nature of LP, the available treatment options, and the importance of ongoing follow-up can help to enhance treatment adherence and improve overall outcomes.

References
  1. Le Cleach L, Chosidow O. Clinical practice. Lichen planus. N Engl J Med. 2012;366:723-732. doi:10.1056/NEJMcp1103641
  2. Handa S, Sahoo B. Childhood lichen planus: a study of 87 cases. Int J Dermatol. 2002;41:423-427. doi:10.1046/j.1365-4362.2002.01522.x
  3. George J, Murray T, Bain M. Generalized, eruptive lichen planus in a pediatric patient. Contemp Pediatr. 2022;39:32-34. 
  4. Arnold DL, Krishnamurthy K. Lichen planus. StatPearls [Internet]. Updated June 1, 2023. Accessed August 12, 2024. https://www.ncbi.nlm.nih.gov/books/NBK526126/
  5. Weston G, Payette M. Update on lichen planus and its clinical variants. Int J Womens Dermatol. 2015;1:140-149. doi:10.1016/j.ijwd.2015.04.001
  6. Mutalik SD, Belgaumkar VA, Rasal YD. Current perspectives in the treatment of childhood lichen planus. Indian J Paediatr Dermatol. 2021;22:316-325. doi:10.4103/ijpd.ijpd_165_20
  7. Usatine RP, Tinitigan M. Diagnosis and treatment of lichen planus. Am Fam Physician. 2011;84:53-60.
  8. Thomas LW, Elsensohn A, Bergheim T, et al. Intramuscular steroids in the treatment of dermatologic disease: a systematic review. J Drugs Dermatol. 2018;17:323-329.
  9. Gorouhi F, Davari P, Fazel N. Cutaneous and mucosal lichen planus: a comprehensive review of clinical subtypes, risk factors, diagnosis, and prognosis. ScientificWorldJournal. 2014;2014:742826. doi:10.1155/2014/742826
Article PDF
Author and Disclosure Information

Dr. Li is from Nuvance Health Vassar Brothers Medical Center, Poughkeepsie, New York. Dr. Parsa is from HCA Florida Orange Park Hospital. Drs. Ansari, Nguyen, and Skopit are from the Department of Dermatology, Larkin Hospital South Miami, Florida.

The authors report no conflict of interest.

Correspondence: Abdul Ansari, DO, Department of Dermatology, Larkin Hospital South Miami, 7031 SW 62nd Ave, South Miami, FL 33143 ([email protected]).

Cutis. 2024 September;114(3):97-98. doi:10.12788/cutis.1086

Issue
Cutis - 114(3)
Publications
Topics
Page Number
97-98
Sections
Author and Disclosure Information

Dr. Li is from Nuvance Health Vassar Brothers Medical Center, Poughkeepsie, New York. Dr. Parsa is from HCA Florida Orange Park Hospital. Drs. Ansari, Nguyen, and Skopit are from the Department of Dermatology, Larkin Hospital South Miami, Florida.

The authors report no conflict of interest.

Correspondence: Abdul Ansari, DO, Department of Dermatology, Larkin Hospital South Miami, 7031 SW 62nd Ave, South Miami, FL 33143 ([email protected]).

Cutis. 2024 September;114(3):97-98. doi:10.12788/cutis.1086

Author and Disclosure Information

Dr. Li is from Nuvance Health Vassar Brothers Medical Center, Poughkeepsie, New York. Dr. Parsa is from HCA Florida Orange Park Hospital. Drs. Ansari, Nguyen, and Skopit are from the Department of Dermatology, Larkin Hospital South Miami, Florida.

The authors report no conflict of interest.

Correspondence: Abdul Ansari, DO, Department of Dermatology, Larkin Hospital South Miami, 7031 SW 62nd Ave, South Miami, FL 33143 ([email protected]).

Cutis. 2024 September;114(3):97-98. doi:10.12788/cutis.1086

Article PDF
Article PDF

Practice Gap

Lichen planus (LP) is an inflammatory cutaneous disorder. Although it often is characterized by the 6 Ps—pruritic, polygonal, planar, purple, papules, and plaques with a predilection for the wrists and ankles—the presentation can vary in morphology and distribution.1-5 With an incidence of approximately 1% in the general population, LP is undoubtedly uncommon.1 Its prevalence in the pediatric population is especially low, with only 2% to 3% of cases manifesting in individuals younger than 20 years.2

Generalized LP (also referred to as eruptive or exanthematous LP) is a rarely reported clinical subtype in which lesions are disseminated or spread rapidly.5 The rarity of generalized LP in children often leads to misdiagnosis or delayed treatment, impacting the patient’s quality of life. Thus, there is a need for heightened awareness among clinicians on the variable presentation of LP in the pediatric population. Incorporating a punch biopsy for the diagnosis of LP when lesions manifest as widespread, erythematous to violaceous, flat-topped papules or plaques, along with the addition of an intramuscular (IM) injection in the treatment plan, improves overall patient outcomes.

Tools and Techniques

A detailed physical examination followed by a punch biopsy was critical for the diagnosis of generalized LP in a 7-year-old Black girl. The examination revealed a widespread distribution of dark, violaceous, polygonal, shiny, flat-topped, firm papules coalescing into plaques across the entire body, with a greater predilection for the legs and overlying joints (Figure, A). Some lesions exhibited fine, silver-white, reticular patterns consistent with Wickham striae. Notably, there was no involvement of the scalp, nails, or mucosal surfaces.

A, Diffuse, dark, violaceous, polygonal, shiny, flat-topped, firm papules coalescing into plaques on the legs and overlying the joints in a 7-year-old girl with generalized lichen planus. B, Combination therapy with clobetasol cream 0.025% and 0.5 cc of intramuscular triamcinolone 40 mg/mL resulted in improvement of lesions and residual hyperpigmentation at 2-week follow-up.

The patient had no relevant medical or family history of skin disease and no recent history of illness. She previously was treated by a pediatrician with triamcinolone cream 0.1%, a course of oral cephalexin, and oral cetirizine 10 mg once daily without relief of symptoms.

Although the clinical presentation was consistent with LP, the differential diagnosis included lichen simplex chronicus, atopic dermatitis, psoriasis, and generalized granuloma annulare. To address the need for early recognition of LP in pediatric patients, a punch biopsy of a lesion on the left anterior thigh was performed and showed lichenoid interface dermatitis—a pivotal finding in distinguishing LP from other conditions in the differential.

Given the patient’s age and severity of the LP, a combination of topical and systemic therapies was prescribed—clobetasol cream 0.025% twice daily and 1 injection of 0.5 cc of IM triamcinolone acetonide 40 mg/mL. This regimen was guided by the efficacy of IM injections in providing prompt symptomatic relief, particularly for patients with extensive disease or for those whose condition is refractory to topical treatments.6 Our patient achieved remarkable improvement at 2-week ­follow-up (Figure, B), without any observed adverse effects. At that time, the patient’s mother refused further systemic treatment and opted for only the topical therapy as well as natural light therapy.

Practice Implications

Timely and accurate diagnosis of LP in pediatric patients, especially those with skin of color, is crucial. Early intervention is especially important in mitigating the risk for chronic symptoms and preventing potential scarring, which tends to be more pronounced and challenging to treat in individuals with darker skin tones.7 Although not present in our patient, it is important to note that LP can affect the face (including the eyelids) as well as the palms and soles in pediatric patients with skin of color.

The most common approach to management of pediatric LP involves the use of a topical corticosteroid and an oral antihistamine, but the recalcitrant and generalized distribution of lesions warrants the administration of a systemic corticosteroid regardless of the patient’s age.6 In our patient, prompt administration of low-dose IM triamcinolone was both crucial and beneficial. Although an underutilized approach, IM triamcinolone helps to prevent the progression of lesions to the scalp, nails, and mucosa while also reducing inflammation and pruritus in glabrous skin.8

Triamcinolone acetonide injections—­administered at concentrations of 5 to 40 mg/mL—directly into the lesion (0.5–1 cc per 2 cm2) are highly effective in managing recalcitrant thickened lesions such as those seen in hypertrophic LP and palmoplantar LP.6 This treatment is particularly beneficial when lesions are unresponsive to topical therapies. Administered every 3 to 6 weeks, these injections provide rapid symptom relief, typically within 72 hours,6 while also contributing to the reduction of lesion size and thickness over time. The concentration of triamcinolone acetonide should be selected based on the lesion’s severity, with higher concentrations reserved for thicker, more resistant lesions. More frequent injections may be warranted in cases in which rapid lesion reduction is necessary, while less frequent sessions may suffice for maintenance therapy. It is important to follow patients closely for adverse effects, such as signs of local skin atrophy or hypopigmentation, and to adjust the dose or frequency accordingly. To mitigate these risks, consider using the lowest effective concentration and rotating injection sites if treating multiple lesions. Additionally, combining intralesional corticosteroids with topical therapies can enhance outcomes, particularly in cases in which monotherapy is insufficient.

Patients should be monitored vigilantly for complications of LP. The risk for postinflammatory hyperpigmentation is a particular concern for patients with skin of color. Other complications of untreated LP include nail deformities and scarring alopecia.9 Regular and thorough follow-ups every few months to monitor scalp, mucosal, and genital involvement are essential to manage this risk effectively.

Furthermore, patient education is key. Informing patients and their caregivers about the nature of LP, the available treatment options, and the importance of ongoing follow-up can help to enhance treatment adherence and improve overall outcomes.

Practice Gap

Lichen planus (LP) is an inflammatory cutaneous disorder. Although it often is characterized by the 6 Ps—pruritic, polygonal, planar, purple, papules, and plaques with a predilection for the wrists and ankles—the presentation can vary in morphology and distribution.1-5 With an incidence of approximately 1% in the general population, LP is undoubtedly uncommon.1 Its prevalence in the pediatric population is especially low, with only 2% to 3% of cases manifesting in individuals younger than 20 years.2

Generalized LP (also referred to as eruptive or exanthematous LP) is a rarely reported clinical subtype in which lesions are disseminated or spread rapidly.5 The rarity of generalized LP in children often leads to misdiagnosis or delayed treatment, impacting the patient’s quality of life. Thus, there is a need for heightened awareness among clinicians on the variable presentation of LP in the pediatric population. Incorporating a punch biopsy for the diagnosis of LP when lesions manifest as widespread, erythematous to violaceous, flat-topped papules or plaques, along with the addition of an intramuscular (IM) injection in the treatment plan, improves overall patient outcomes.

Tools and Techniques

A detailed physical examination followed by a punch biopsy was critical for the diagnosis of generalized LP in a 7-year-old Black girl. The examination revealed a widespread distribution of dark, violaceous, polygonal, shiny, flat-topped, firm papules coalescing into plaques across the entire body, with a greater predilection for the legs and overlying joints (Figure, A). Some lesions exhibited fine, silver-white, reticular patterns consistent with Wickham striae. Notably, there was no involvement of the scalp, nails, or mucosal surfaces.

A, Diffuse, dark, violaceous, polygonal, shiny, flat-topped, firm papules coalescing into plaques on the legs and overlying the joints in a 7-year-old girl with generalized lichen planus. B, Combination therapy with clobetasol cream 0.025% and 0.5 cc of intramuscular triamcinolone 40 mg/mL resulted in improvement of lesions and residual hyperpigmentation at 2-week follow-up.

The patient had no relevant medical or family history of skin disease and no recent history of illness. She previously was treated by a pediatrician with triamcinolone cream 0.1%, a course of oral cephalexin, and oral cetirizine 10 mg once daily without relief of symptoms.

Although the clinical presentation was consistent with LP, the differential diagnosis included lichen simplex chronicus, atopic dermatitis, psoriasis, and generalized granuloma annulare. To address the need for early recognition of LP in pediatric patients, a punch biopsy of a lesion on the left anterior thigh was performed and showed lichenoid interface dermatitis—a pivotal finding in distinguishing LP from other conditions in the differential.

Given the patient’s age and severity of the LP, a combination of topical and systemic therapies was prescribed—clobetasol cream 0.025% twice daily and 1 injection of 0.5 cc of IM triamcinolone acetonide 40 mg/mL. This regimen was guided by the efficacy of IM injections in providing prompt symptomatic relief, particularly for patients with extensive disease or for those whose condition is refractory to topical treatments.6 Our patient achieved remarkable improvement at 2-week ­follow-up (Figure, B), without any observed adverse effects. At that time, the patient’s mother refused further systemic treatment and opted for only the topical therapy as well as natural light therapy.

Practice Implications

Timely and accurate diagnosis of LP in pediatric patients, especially those with skin of color, is crucial. Early intervention is especially important in mitigating the risk for chronic symptoms and preventing potential scarring, which tends to be more pronounced and challenging to treat in individuals with darker skin tones.7 Although not present in our patient, it is important to note that LP can affect the face (including the eyelids) as well as the palms and soles in pediatric patients with skin of color.

The most common approach to management of pediatric LP involves the use of a topical corticosteroid and an oral antihistamine, but the recalcitrant and generalized distribution of lesions warrants the administration of a systemic corticosteroid regardless of the patient’s age.6 In our patient, prompt administration of low-dose IM triamcinolone was both crucial and beneficial. Although an underutilized approach, IM triamcinolone helps to prevent the progression of lesions to the scalp, nails, and mucosa while also reducing inflammation and pruritus in glabrous skin.8

Triamcinolone acetonide injections—­administered at concentrations of 5 to 40 mg/mL—directly into the lesion (0.5–1 cc per 2 cm2) are highly effective in managing recalcitrant thickened lesions such as those seen in hypertrophic LP and palmoplantar LP.6 This treatment is particularly beneficial when lesions are unresponsive to topical therapies. Administered every 3 to 6 weeks, these injections provide rapid symptom relief, typically within 72 hours,6 while also contributing to the reduction of lesion size and thickness over time. The concentration of triamcinolone acetonide should be selected based on the lesion’s severity, with higher concentrations reserved for thicker, more resistant lesions. More frequent injections may be warranted in cases in which rapid lesion reduction is necessary, while less frequent sessions may suffice for maintenance therapy. It is important to follow patients closely for adverse effects, such as signs of local skin atrophy or hypopigmentation, and to adjust the dose or frequency accordingly. To mitigate these risks, consider using the lowest effective concentration and rotating injection sites if treating multiple lesions. Additionally, combining intralesional corticosteroids with topical therapies can enhance outcomes, particularly in cases in which monotherapy is insufficient.

Patients should be monitored vigilantly for complications of LP. The risk for postinflammatory hyperpigmentation is a particular concern for patients with skin of color. Other complications of untreated LP include nail deformities and scarring alopecia.9 Regular and thorough follow-ups every few months to monitor scalp, mucosal, and genital involvement are essential to manage this risk effectively.

Furthermore, patient education is key. Informing patients and their caregivers about the nature of LP, the available treatment options, and the importance of ongoing follow-up can help to enhance treatment adherence and improve overall outcomes.

References
  1. Le Cleach L, Chosidow O. Clinical practice. Lichen planus. N Engl J Med. 2012;366:723-732. doi:10.1056/NEJMcp1103641
  2. Handa S, Sahoo B. Childhood lichen planus: a study of 87 cases. Int J Dermatol. 2002;41:423-427. doi:10.1046/j.1365-4362.2002.01522.x
  3. George J, Murray T, Bain M. Generalized, eruptive lichen planus in a pediatric patient. Contemp Pediatr. 2022;39:32-34. 
  4. Arnold DL, Krishnamurthy K. Lichen planus. StatPearls [Internet]. Updated June 1, 2023. Accessed August 12, 2024. https://www.ncbi.nlm.nih.gov/books/NBK526126/
  5. Weston G, Payette M. Update on lichen planus and its clinical variants. Int J Womens Dermatol. 2015;1:140-149. doi:10.1016/j.ijwd.2015.04.001
  6. Mutalik SD, Belgaumkar VA, Rasal YD. Current perspectives in the treatment of childhood lichen planus. Indian J Paediatr Dermatol. 2021;22:316-325. doi:10.4103/ijpd.ijpd_165_20
  7. Usatine RP, Tinitigan M. Diagnosis and treatment of lichen planus. Am Fam Physician. 2011;84:53-60.
  8. Thomas LW, Elsensohn A, Bergheim T, et al. Intramuscular steroids in the treatment of dermatologic disease: a systematic review. J Drugs Dermatol. 2018;17:323-329.
  9. Gorouhi F, Davari P, Fazel N. Cutaneous and mucosal lichen planus: a comprehensive review of clinical subtypes, risk factors, diagnosis, and prognosis. ScientificWorldJournal. 2014;2014:742826. doi:10.1155/2014/742826
References
  1. Le Cleach L, Chosidow O. Clinical practice. Lichen planus. N Engl J Med. 2012;366:723-732. doi:10.1056/NEJMcp1103641
  2. Handa S, Sahoo B. Childhood lichen planus: a study of 87 cases. Int J Dermatol. 2002;41:423-427. doi:10.1046/j.1365-4362.2002.01522.x
  3. George J, Murray T, Bain M. Generalized, eruptive lichen planus in a pediatric patient. Contemp Pediatr. 2022;39:32-34. 
  4. Arnold DL, Krishnamurthy K. Lichen planus. StatPearls [Internet]. Updated June 1, 2023. Accessed August 12, 2024. https://www.ncbi.nlm.nih.gov/books/NBK526126/
  5. Weston G, Payette M. Update on lichen planus and its clinical variants. Int J Womens Dermatol. 2015;1:140-149. doi:10.1016/j.ijwd.2015.04.001
  6. Mutalik SD, Belgaumkar VA, Rasal YD. Current perspectives in the treatment of childhood lichen planus. Indian J Paediatr Dermatol. 2021;22:316-325. doi:10.4103/ijpd.ijpd_165_20
  7. Usatine RP, Tinitigan M. Diagnosis and treatment of lichen planus. Am Fam Physician. 2011;84:53-60.
  8. Thomas LW, Elsensohn A, Bergheim T, et al. Intramuscular steroids in the treatment of dermatologic disease: a systematic review. J Drugs Dermatol. 2018;17:323-329.
  9. Gorouhi F, Davari P, Fazel N. Cutaneous and mucosal lichen planus: a comprehensive review of clinical subtypes, risk factors, diagnosis, and prognosis. ScientificWorldJournal. 2014;2014:742826. doi:10.1155/2014/742826
Issue
Cutis - 114(3)
Issue
Cutis - 114(3)
Page Number
97-98
Page Number
97-98
Publications
Publications
Topics
Article Type
Display Headline
Enhanced Care for Pediatric Patients With Generalized Lichen Planus: Diagnosis and Treatment Tips
Display Headline
Enhanced Care for Pediatric Patients With Generalized Lichen Planus: Diagnosis and Treatment Tips
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Use ProPublica
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article
Article PDF Media

Customized Dermal Curette: An Alternative and Effective Shaving Tool in Nail Surgery

Article Type
Changed
Display Headline
Customized Dermal Curette: An Alternative and Effective Shaving Tool in Nail Surgery

Practice Gap

Longitudinal melanonychia (LM) is characterized by the presence of a dark brown, longitudinal, pigmented band on the nail unit, often caused by melanocytic activation or melanocytic hyperplasia in the nail matrix. Distinguishing between benign and early malignant LM is crucial due to their similar clinical presentations.1 Hence, surgical excision of the pigmented nail matrix followed by histopathologic examination is a common procedure aimed at managing LM and reducing the risk for delayed diagnosis of subungual melanoma.

Tangential matrix excision combined with the nail window technique has emerged as a common and favored surgical strategy for managing LM.2 This method is highly valued for its ability to minimize the risk for severe permanent nail dystrophy and effectively reduce postsurgical pigmentation recurrence.

The procedure begins with the creation of a matrix window along the lateral edge of the pigmented band followed by 1 lateral incision carefully made on each side of the nail fold. This meticulous approach allows for the complete exposure of the pigmented lesion. Subsequently, the nail fold is separated from the dorsal surface of the nail plate to facilitate access to the pigmented nail matrix. Finally, the target pigmented area is excised using a scalpel.

Despite the recognized efficacy of this procedure, challenges do arise, particularly when the width of the pigmented matrix lesion is narrow. Holding the scalpel horizontally to ensure precise excision can prove to be demanding, leading to difficulty achieving complete lesion removal and obtaining the desired cosmetic outcomes. As such, there is a clear need to explore alternative tools that can effectively address these challenges while ensuring optimal surgical outcomes for patients with LM. We propose the use of the customized dermal curette.

The Technique

An improved curette tool is a practical solution for complete removal of the pigmented nail matrix. This enhanced instrument is crafted from a sterile disposable dermal curette with its top flattened using a needle holder(Figure 1). Termed the customized dermal curette, this device is a simple yet accurate tool for the precise excision of pigmented lesions within the nail matrix. Importantly, it offers versatility by accommodating different widths of pigmented lesions through the availability of various sizes of dermal curettes (Figure 2).

FIGURE 1. The customized dermal curette is crafted from a sterile disposable dermal curette with its top flattened using a needle holder and can be used to manage longitudinal melanonychia.

FIGURE 2. A, A sterile disposable dermal curette (2.0 mm) is used for excision of a pigmented lesion on the nail matrix. B, The improved curette tool achieves more precise tissue excision, leading to uniform tissue thickness and integrity.

Histopathologically, we have found that the scalpel technique may lead to variable tissue removal, resulting in differences in tissue thickness, fragility, and completeness (Figure 3A). Conversely, the customized dermal curette consistently provides more accurate tissue excision, resulting in uniform tissue thickness and integrity (Figure 3B).

FIGURE 3. A, Histopathologically, excision of a pigmented lesion on the nail matrix with a scalpel may yield variable tissue removal, resulting in differences in tissue thickness, fragility, and completeness (H&E, original magnification ×5). B, Excision with the customized dermal curette provides more accurate tissue excision, resulting in uniform tissue thickness and integrity (H&E, original magnification ×5).

Practice Implications

Compared to the traditional scalpel, this modified tool offers distinct advantages. Specifically, the customized dermal curette provides enhanced maneuverability and control during the procedure, thereby improving the overall efficacy of the excision process. It also offers a more accurate approach to completely remove pigmented bands, which reduces the risk for postoperative recurrence. The simplicity, affordability, and ease of operation associated with customized dermal curettes holds promise as an effective alternative for tissue shaving, especially in cases involving narrow pigmented matrix lesions, thereby addressing a notable practice gap and enhancing patient care.

References
  1. Tan WC, Wang DY, Seghers AC, et al. Should we biopsy melanonychia striata in Asian children? a retrospective observational study. Pediatr Dermatol. 2019;36:864-868. doi:10.1111/pde.13934
  2. Zhou Y, Chen W, Liu ZR, et al. Modified shave surgery combined with nail window technique for the treatment of longitudinal melanonychia: evaluation of the method on a series of 67 cases. J Am Acad Dermatol. 2019;81:717-722. doi:10.1016/j.jaad.2019.03.065
Article PDF
Author and Disclosure Information

 

From the Department of Dermatology, The Affiliated Hospital of Guizhou Medical University, Guiyang, China.

The authors report no conflict of interest.

Correspondence: Hongguang Lu, MD, PhD, Department of Dermatology, The Affiliated Hospital of Guizhou Medical University, No.28 Guiyi St, Guiyang, Guizhou 550001, China ([email protected]).

Cutis. 2024 August;114(2):65-66. doi:10.12788/cutis.1068

Issue
Cutis - 114(2)
Publications
Topics
Page Number
65-66
Sections
Author and Disclosure Information

 

From the Department of Dermatology, The Affiliated Hospital of Guizhou Medical University, Guiyang, China.

The authors report no conflict of interest.

Correspondence: Hongguang Lu, MD, PhD, Department of Dermatology, The Affiliated Hospital of Guizhou Medical University, No.28 Guiyi St, Guiyang, Guizhou 550001, China ([email protected]).

Cutis. 2024 August;114(2):65-66. doi:10.12788/cutis.1068

Author and Disclosure Information

 

From the Department of Dermatology, The Affiliated Hospital of Guizhou Medical University, Guiyang, China.

The authors report no conflict of interest.

Correspondence: Hongguang Lu, MD, PhD, Department of Dermatology, The Affiliated Hospital of Guizhou Medical University, No.28 Guiyi St, Guiyang, Guizhou 550001, China ([email protected]).

Cutis. 2024 August;114(2):65-66. doi:10.12788/cutis.1068

Article PDF
Article PDF

Practice Gap

Longitudinal melanonychia (LM) is characterized by the presence of a dark brown, longitudinal, pigmented band on the nail unit, often caused by melanocytic activation or melanocytic hyperplasia in the nail matrix. Distinguishing between benign and early malignant LM is crucial due to their similar clinical presentations.1 Hence, surgical excision of the pigmented nail matrix followed by histopathologic examination is a common procedure aimed at managing LM and reducing the risk for delayed diagnosis of subungual melanoma.

Tangential matrix excision combined with the nail window technique has emerged as a common and favored surgical strategy for managing LM.2 This method is highly valued for its ability to minimize the risk for severe permanent nail dystrophy and effectively reduce postsurgical pigmentation recurrence.

The procedure begins with the creation of a matrix window along the lateral edge of the pigmented band followed by 1 lateral incision carefully made on each side of the nail fold. This meticulous approach allows for the complete exposure of the pigmented lesion. Subsequently, the nail fold is separated from the dorsal surface of the nail plate to facilitate access to the pigmented nail matrix. Finally, the target pigmented area is excised using a scalpel.

Despite the recognized efficacy of this procedure, challenges do arise, particularly when the width of the pigmented matrix lesion is narrow. Holding the scalpel horizontally to ensure precise excision can prove to be demanding, leading to difficulty achieving complete lesion removal and obtaining the desired cosmetic outcomes. As such, there is a clear need to explore alternative tools that can effectively address these challenges while ensuring optimal surgical outcomes for patients with LM. We propose the use of the customized dermal curette.

The Technique

An improved curette tool is a practical solution for complete removal of the pigmented nail matrix. This enhanced instrument is crafted from a sterile disposable dermal curette with its top flattened using a needle holder(Figure 1). Termed the customized dermal curette, this device is a simple yet accurate tool for the precise excision of pigmented lesions within the nail matrix. Importantly, it offers versatility by accommodating different widths of pigmented lesions through the availability of various sizes of dermal curettes (Figure 2).

FIGURE 1. The customized dermal curette is crafted from a sterile disposable dermal curette with its top flattened using a needle holder and can be used to manage longitudinal melanonychia.

FIGURE 2. A, A sterile disposable dermal curette (2.0 mm) is used for excision of a pigmented lesion on the nail matrix. B, The improved curette tool achieves more precise tissue excision, leading to uniform tissue thickness and integrity.

Histopathologically, we have found that the scalpel technique may lead to variable tissue removal, resulting in differences in tissue thickness, fragility, and completeness (Figure 3A). Conversely, the customized dermal curette consistently provides more accurate tissue excision, resulting in uniform tissue thickness and integrity (Figure 3B).

FIGURE 3. A, Histopathologically, excision of a pigmented lesion on the nail matrix with a scalpel may yield variable tissue removal, resulting in differences in tissue thickness, fragility, and completeness (H&E, original magnification ×5). B, Excision with the customized dermal curette provides more accurate tissue excision, resulting in uniform tissue thickness and integrity (H&E, original magnification ×5).

Practice Implications

Compared to the traditional scalpel, this modified tool offers distinct advantages. Specifically, the customized dermal curette provides enhanced maneuverability and control during the procedure, thereby improving the overall efficacy of the excision process. It also offers a more accurate approach to completely remove pigmented bands, which reduces the risk for postoperative recurrence. The simplicity, affordability, and ease of operation associated with customized dermal curettes holds promise as an effective alternative for tissue shaving, especially in cases involving narrow pigmented matrix lesions, thereby addressing a notable practice gap and enhancing patient care.

Practice Gap

Longitudinal melanonychia (LM) is characterized by the presence of a dark brown, longitudinal, pigmented band on the nail unit, often caused by melanocytic activation or melanocytic hyperplasia in the nail matrix. Distinguishing between benign and early malignant LM is crucial due to their similar clinical presentations.1 Hence, surgical excision of the pigmented nail matrix followed by histopathologic examination is a common procedure aimed at managing LM and reducing the risk for delayed diagnosis of subungual melanoma.

Tangential matrix excision combined with the nail window technique has emerged as a common and favored surgical strategy for managing LM.2 This method is highly valued for its ability to minimize the risk for severe permanent nail dystrophy and effectively reduce postsurgical pigmentation recurrence.

The procedure begins with the creation of a matrix window along the lateral edge of the pigmented band followed by 1 lateral incision carefully made on each side of the nail fold. This meticulous approach allows for the complete exposure of the pigmented lesion. Subsequently, the nail fold is separated from the dorsal surface of the nail plate to facilitate access to the pigmented nail matrix. Finally, the target pigmented area is excised using a scalpel.

Despite the recognized efficacy of this procedure, challenges do arise, particularly when the width of the pigmented matrix lesion is narrow. Holding the scalpel horizontally to ensure precise excision can prove to be demanding, leading to difficulty achieving complete lesion removal and obtaining the desired cosmetic outcomes. As such, there is a clear need to explore alternative tools that can effectively address these challenges while ensuring optimal surgical outcomes for patients with LM. We propose the use of the customized dermal curette.

The Technique

An improved curette tool is a practical solution for complete removal of the pigmented nail matrix. This enhanced instrument is crafted from a sterile disposable dermal curette with its top flattened using a needle holder(Figure 1). Termed the customized dermal curette, this device is a simple yet accurate tool for the precise excision of pigmented lesions within the nail matrix. Importantly, it offers versatility by accommodating different widths of pigmented lesions through the availability of various sizes of dermal curettes (Figure 2).

FIGURE 1. The customized dermal curette is crafted from a sterile disposable dermal curette with its top flattened using a needle holder and can be used to manage longitudinal melanonychia.

FIGURE 2. A, A sterile disposable dermal curette (2.0 mm) is used for excision of a pigmented lesion on the nail matrix. B, The improved curette tool achieves more precise tissue excision, leading to uniform tissue thickness and integrity.

Histopathologically, we have found that the scalpel technique may lead to variable tissue removal, resulting in differences in tissue thickness, fragility, and completeness (Figure 3A). Conversely, the customized dermal curette consistently provides more accurate tissue excision, resulting in uniform tissue thickness and integrity (Figure 3B).

FIGURE 3. A, Histopathologically, excision of a pigmented lesion on the nail matrix with a scalpel may yield variable tissue removal, resulting in differences in tissue thickness, fragility, and completeness (H&E, original magnification ×5). B, Excision with the customized dermal curette provides more accurate tissue excision, resulting in uniform tissue thickness and integrity (H&E, original magnification ×5).

Practice Implications

Compared to the traditional scalpel, this modified tool offers distinct advantages. Specifically, the customized dermal curette provides enhanced maneuverability and control during the procedure, thereby improving the overall efficacy of the excision process. It also offers a more accurate approach to completely remove pigmented bands, which reduces the risk for postoperative recurrence. The simplicity, affordability, and ease of operation associated with customized dermal curettes holds promise as an effective alternative for tissue shaving, especially in cases involving narrow pigmented matrix lesions, thereby addressing a notable practice gap and enhancing patient care.

References
  1. Tan WC, Wang DY, Seghers AC, et al. Should we biopsy melanonychia striata in Asian children? a retrospective observational study. Pediatr Dermatol. 2019;36:864-868. doi:10.1111/pde.13934
  2. Zhou Y, Chen W, Liu ZR, et al. Modified shave surgery combined with nail window technique for the treatment of longitudinal melanonychia: evaluation of the method on a series of 67 cases. J Am Acad Dermatol. 2019;81:717-722. doi:10.1016/j.jaad.2019.03.065
References
  1. Tan WC, Wang DY, Seghers AC, et al. Should we biopsy melanonychia striata in Asian children? a retrospective observational study. Pediatr Dermatol. 2019;36:864-868. doi:10.1111/pde.13934
  2. Zhou Y, Chen W, Liu ZR, et al. Modified shave surgery combined with nail window technique for the treatment of longitudinal melanonychia: evaluation of the method on a series of 67 cases. J Am Acad Dermatol. 2019;81:717-722. doi:10.1016/j.jaad.2019.03.065
Issue
Cutis - 114(2)
Issue
Cutis - 114(2)
Page Number
65-66
Page Number
65-66
Publications
Publications
Topics
Article Type
Display Headline
Customized Dermal Curette: An Alternative and Effective Shaving Tool in Nail Surgery
Display Headline
Customized Dermal Curette: An Alternative and Effective Shaving Tool in Nail Surgery
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Use ProPublica
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article
Article PDF Media

Two Techniques to Avoid Cyst Spray During Excision

Article Type
Changed
Display Headline
Two Techniques to Avoid Cyst Spray During Excision

Practice Gap

Epidermoid cysts are asymptomatic, well-circumscribed, mobile, subcutaneous masses that elevate the skin. Also known as epidermal, keratin, or infundibular cysts, epidermoid cysts are caused by proliferation of surface epidermoid cells within the dermis and can arise anywhere on the body, most commonly on the face, neck, and trunk.1 Cutaneous cysts often contain fluid or semifluid contents and can be aesthetically displeasing or cause mild pain, prompting patients to seek removal. Definitive treatment of epidermoid cysts is complete surgical removal,2 which can be performed in office in a sterile or clean manner by either dermatologists or primary care providers.

Prior to incision, a local anesthetic—commonly lidocaine with epinephrine—is injected in the region surrounding the cyst sac so as not to rupture the cyst wall. Maintaining the cyst wall throughout the procedure ensures total cyst removal and minimizes the risk for recurrence. However, it often is difficult to approximate the cyst border because it cannot be visualized prior to incision.

Throughout the duration of the procedure, cyst contents may suddenly spray out of the area and pose a risk to providers and their staff (Figure, A). Even with careful application around the periphery, either puncture or ­pericystic anesthesia between the cyst wall and the dermis can lead to splatter. Larger and wider peripheral anesthesia may not be possible given a shortage of ­lidocaine and a desire to minimize injection. Even with meticulous use of personal protective equipment in cutaneous surgery, infectious organisms found in ruptured cysts and abscesses may spray the surgical field.3 Therefore, it is in our best interest to minimize the trajectory of cyst spray contents.

The Tools

We have employed 2 simple techniques using equipment normally found on a standard surgical tray for easy safe injection of cysts. Supplies needed include 4×4-inch gauze pads, alcohol and chlorhexidine, a marker, all instruments necessary for cyst excision, and a small clear biohazard bag.

The Technique

Prior to covering the cyst, care is taken to locate the cyst opening. At times, a comedo or punctum can be seen overlying the cyst bulge. We mark the lumen and cyst opening with a surgical marker. If the pore is not easily identified, we draw an 8-mm circle around the mound of the cyst. 

One option is to apply a gauze pad over the cyst to allow for stabilization of the surgical field and blanket the area from splatter (Figure, B). Then we cover the cyst using antiseptic-soaked gauze as a protective barrier to avoid potentially contaminated spray. This tool can be constructed from a 4×4-inch gauze pad with the addition of alcohol and chlorhexidine. When the cyst is covered, the surgeon can inject the lesion and surrounding tissue without biohazard splatter.

A, During surgical excision of an epidermoid cyst, contents may spray out and pose a risk to clinicians and staff. B, Application of an antisepticsoaked gauze pad over the cyst allows for stabilization of the surgical field and blankets the area from splatter. C, Alternatively, the cyst can be covered with a small clear biohazard bag to catch any spraying contents while allowing visualization of the surgical field.

Another method is to cover the cyst with a small clear biohazard bag (Figure, C). When injecting anesthetic through the bag, the spray is captured by the bag and does not reach the surgeon or staff. This method is potentially more effective given that the cyst can still be visualized fully for more accurate injection.

Practice Implications

Outpatient surgical excision is a common effective procedure for epidermoid cysts. However, it is not uncommon for cyst contents to spray during the injection of anesthetic, posing a nuisance to the surgeon, health care staff, and patient. The technique of covering the lesion with antiseptic-soaked gauze or a small clear biohazard bag prevents cyst contents from spraying and reduces risk for contamination. In addition to these protective benefits, the use of readily available items replaces the need to order a splatter control shield.

Limitations—Although we seldom see spray using our technique, covering the cyst with gauze may disguise the region of interest and interfere with accurate incision. Marking the lesion prior to anesthesia administration or using a clear biohazard bag minimizes difficulty visualizing the cyst opening.

References
  1. Zito PM, Scharf R. Epidermoid cyst. StatPearls [Internet]. Updated August 8, 2023. Accessed June 13, 2024. https://www.ncbi.nlm.nih.gov/books/NBK499974
  2. Weir CB, St. Hilaire NJ. Epidermal inclusion cyst. StatPearls [Internet]. Updated August 8, 2023. Accessed June3, 2024. https://www.ncbi.nlm.nih.gov/books/NBK532310/
  3. Kuniyuki S, Yoshida Y, Maekawa N, et al. Bacteriological study of epidermal cysts. Acta Derm Venereol. 2018;88:23-25. doi:10.2340/00015555-0348
Article PDF
Author and Disclosure Information

 

Bita Tristani-Firouzi is from Pomona College, Claremont, California. Elliott D. Herron is from the University of Alabama Birmingham. Dr. Hull is from the Department of Dermatology, University of Utah, Salt Lake City. Dr. Herron is from Herron Dermatology and Laser, Montgomery, Alabama.

The authors report no conflict of interest.

Correspondence: Mark D. Herron, MD, Herron Dermatology and Laser, 7260 Halcyon Summit Dr, Montgomery, AL 36117 ([email protected]).

Cutis. 2024 July;114(1):11, 26. doi:10.12788/cutis.1047

Issue
Cutis - 114(1)
Publications
Topics
Page Number
11,26
Sections
Author and Disclosure Information

 

Bita Tristani-Firouzi is from Pomona College, Claremont, California. Elliott D. Herron is from the University of Alabama Birmingham. Dr. Hull is from the Department of Dermatology, University of Utah, Salt Lake City. Dr. Herron is from Herron Dermatology and Laser, Montgomery, Alabama.

The authors report no conflict of interest.

Correspondence: Mark D. Herron, MD, Herron Dermatology and Laser, 7260 Halcyon Summit Dr, Montgomery, AL 36117 ([email protected]).

Cutis. 2024 July;114(1):11, 26. doi:10.12788/cutis.1047

Author and Disclosure Information

 

Bita Tristani-Firouzi is from Pomona College, Claremont, California. Elliott D. Herron is from the University of Alabama Birmingham. Dr. Hull is from the Department of Dermatology, University of Utah, Salt Lake City. Dr. Herron is from Herron Dermatology and Laser, Montgomery, Alabama.

The authors report no conflict of interest.

Correspondence: Mark D. Herron, MD, Herron Dermatology and Laser, 7260 Halcyon Summit Dr, Montgomery, AL 36117 ([email protected]).

Cutis. 2024 July;114(1):11, 26. doi:10.12788/cutis.1047

Article PDF
Article PDF

Practice Gap

Epidermoid cysts are asymptomatic, well-circumscribed, mobile, subcutaneous masses that elevate the skin. Also known as epidermal, keratin, or infundibular cysts, epidermoid cysts are caused by proliferation of surface epidermoid cells within the dermis and can arise anywhere on the body, most commonly on the face, neck, and trunk.1 Cutaneous cysts often contain fluid or semifluid contents and can be aesthetically displeasing or cause mild pain, prompting patients to seek removal. Definitive treatment of epidermoid cysts is complete surgical removal,2 which can be performed in office in a sterile or clean manner by either dermatologists or primary care providers.

Prior to incision, a local anesthetic—commonly lidocaine with epinephrine—is injected in the region surrounding the cyst sac so as not to rupture the cyst wall. Maintaining the cyst wall throughout the procedure ensures total cyst removal and minimizes the risk for recurrence. However, it often is difficult to approximate the cyst border because it cannot be visualized prior to incision.

Throughout the duration of the procedure, cyst contents may suddenly spray out of the area and pose a risk to providers and their staff (Figure, A). Even with careful application around the periphery, either puncture or ­pericystic anesthesia between the cyst wall and the dermis can lead to splatter. Larger and wider peripheral anesthesia may not be possible given a shortage of ­lidocaine and a desire to minimize injection. Even with meticulous use of personal protective equipment in cutaneous surgery, infectious organisms found in ruptured cysts and abscesses may spray the surgical field.3 Therefore, it is in our best interest to minimize the trajectory of cyst spray contents.

The Tools

We have employed 2 simple techniques using equipment normally found on a standard surgical tray for easy safe injection of cysts. Supplies needed include 4×4-inch gauze pads, alcohol and chlorhexidine, a marker, all instruments necessary for cyst excision, and a small clear biohazard bag.

The Technique

Prior to covering the cyst, care is taken to locate the cyst opening. At times, a comedo or punctum can be seen overlying the cyst bulge. We mark the lumen and cyst opening with a surgical marker. If the pore is not easily identified, we draw an 8-mm circle around the mound of the cyst. 

One option is to apply a gauze pad over the cyst to allow for stabilization of the surgical field and blanket the area from splatter (Figure, B). Then we cover the cyst using antiseptic-soaked gauze as a protective barrier to avoid potentially contaminated spray. This tool can be constructed from a 4×4-inch gauze pad with the addition of alcohol and chlorhexidine. When the cyst is covered, the surgeon can inject the lesion and surrounding tissue without biohazard splatter.

A, During surgical excision of an epidermoid cyst, contents may spray out and pose a risk to clinicians and staff. B, Application of an antisepticsoaked gauze pad over the cyst allows for stabilization of the surgical field and blankets the area from splatter. C, Alternatively, the cyst can be covered with a small clear biohazard bag to catch any spraying contents while allowing visualization of the surgical field.

Another method is to cover the cyst with a small clear biohazard bag (Figure, C). When injecting anesthetic through the bag, the spray is captured by the bag and does not reach the surgeon or staff. This method is potentially more effective given that the cyst can still be visualized fully for more accurate injection.

Practice Implications

Outpatient surgical excision is a common effective procedure for epidermoid cysts. However, it is not uncommon for cyst contents to spray during the injection of anesthetic, posing a nuisance to the surgeon, health care staff, and patient. The technique of covering the lesion with antiseptic-soaked gauze or a small clear biohazard bag prevents cyst contents from spraying and reduces risk for contamination. In addition to these protective benefits, the use of readily available items replaces the need to order a splatter control shield.

Limitations—Although we seldom see spray using our technique, covering the cyst with gauze may disguise the region of interest and interfere with accurate incision. Marking the lesion prior to anesthesia administration or using a clear biohazard bag minimizes difficulty visualizing the cyst opening.

Practice Gap

Epidermoid cysts are asymptomatic, well-circumscribed, mobile, subcutaneous masses that elevate the skin. Also known as epidermal, keratin, or infundibular cysts, epidermoid cysts are caused by proliferation of surface epidermoid cells within the dermis and can arise anywhere on the body, most commonly on the face, neck, and trunk.1 Cutaneous cysts often contain fluid or semifluid contents and can be aesthetically displeasing or cause mild pain, prompting patients to seek removal. Definitive treatment of epidermoid cysts is complete surgical removal,2 which can be performed in office in a sterile or clean manner by either dermatologists or primary care providers.

Prior to incision, a local anesthetic—commonly lidocaine with epinephrine—is injected in the region surrounding the cyst sac so as not to rupture the cyst wall. Maintaining the cyst wall throughout the procedure ensures total cyst removal and minimizes the risk for recurrence. However, it often is difficult to approximate the cyst border because it cannot be visualized prior to incision.

Throughout the duration of the procedure, cyst contents may suddenly spray out of the area and pose a risk to providers and their staff (Figure, A). Even with careful application around the periphery, either puncture or ­pericystic anesthesia between the cyst wall and the dermis can lead to splatter. Larger and wider peripheral anesthesia may not be possible given a shortage of ­lidocaine and a desire to minimize injection. Even with meticulous use of personal protective equipment in cutaneous surgery, infectious organisms found in ruptured cysts and abscesses may spray the surgical field.3 Therefore, it is in our best interest to minimize the trajectory of cyst spray contents.

The Tools

We have employed 2 simple techniques using equipment normally found on a standard surgical tray for easy safe injection of cysts. Supplies needed include 4×4-inch gauze pads, alcohol and chlorhexidine, a marker, all instruments necessary for cyst excision, and a small clear biohazard bag.

The Technique

Prior to covering the cyst, care is taken to locate the cyst opening. At times, a comedo or punctum can be seen overlying the cyst bulge. We mark the lumen and cyst opening with a surgical marker. If the pore is not easily identified, we draw an 8-mm circle around the mound of the cyst. 

One option is to apply a gauze pad over the cyst to allow for stabilization of the surgical field and blanket the area from splatter (Figure, B). Then we cover the cyst using antiseptic-soaked gauze as a protective barrier to avoid potentially contaminated spray. This tool can be constructed from a 4×4-inch gauze pad with the addition of alcohol and chlorhexidine. When the cyst is covered, the surgeon can inject the lesion and surrounding tissue without biohazard splatter.

A, During surgical excision of an epidermoid cyst, contents may spray out and pose a risk to clinicians and staff. B, Application of an antisepticsoaked gauze pad over the cyst allows for stabilization of the surgical field and blankets the area from splatter. C, Alternatively, the cyst can be covered with a small clear biohazard bag to catch any spraying contents while allowing visualization of the surgical field.

Another method is to cover the cyst with a small clear biohazard bag (Figure, C). When injecting anesthetic through the bag, the spray is captured by the bag and does not reach the surgeon or staff. This method is potentially more effective given that the cyst can still be visualized fully for more accurate injection.

Practice Implications

Outpatient surgical excision is a common effective procedure for epidermoid cysts. However, it is not uncommon for cyst contents to spray during the injection of anesthetic, posing a nuisance to the surgeon, health care staff, and patient. The technique of covering the lesion with antiseptic-soaked gauze or a small clear biohazard bag prevents cyst contents from spraying and reduces risk for contamination. In addition to these protective benefits, the use of readily available items replaces the need to order a splatter control shield.

Limitations—Although we seldom see spray using our technique, covering the cyst with gauze may disguise the region of interest and interfere with accurate incision. Marking the lesion prior to anesthesia administration or using a clear biohazard bag minimizes difficulty visualizing the cyst opening.

References
  1. Zito PM, Scharf R. Epidermoid cyst. StatPearls [Internet]. Updated August 8, 2023. Accessed June 13, 2024. https://www.ncbi.nlm.nih.gov/books/NBK499974
  2. Weir CB, St. Hilaire NJ. Epidermal inclusion cyst. StatPearls [Internet]. Updated August 8, 2023. Accessed June3, 2024. https://www.ncbi.nlm.nih.gov/books/NBK532310/
  3. Kuniyuki S, Yoshida Y, Maekawa N, et al. Bacteriological study of epidermal cysts. Acta Derm Venereol. 2018;88:23-25. doi:10.2340/00015555-0348
References
  1. Zito PM, Scharf R. Epidermoid cyst. StatPearls [Internet]. Updated August 8, 2023. Accessed June 13, 2024. https://www.ncbi.nlm.nih.gov/books/NBK499974
  2. Weir CB, St. Hilaire NJ. Epidermal inclusion cyst. StatPearls [Internet]. Updated August 8, 2023. Accessed June3, 2024. https://www.ncbi.nlm.nih.gov/books/NBK532310/
  3. Kuniyuki S, Yoshida Y, Maekawa N, et al. Bacteriological study of epidermal cysts. Acta Derm Venereol. 2018;88:23-25. doi:10.2340/00015555-0348
Issue
Cutis - 114(1)
Issue
Cutis - 114(1)
Page Number
11,26
Page Number
11,26
Publications
Publications
Topics
Article Type
Display Headline
Two Techniques to Avoid Cyst Spray During Excision
Display Headline
Two Techniques to Avoid Cyst Spray During Excision
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Use ProPublica
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article
Article PDF Media

Need a Wood Lamp Alternative? Grab Your Smartphone

Article Type
Changed
Display Headline
Need a Wood Lamp Alternative? Grab Your Smartphone

Practice Gap

The Wood lamp commonly is used as a diagnostic tool for pigmentary skin conditions (eg, vitiligo) or skin conditions that exhibit fluorescence (eg, erythrasma).1 Recently, its diagnostic efficacy has extended to scabies, in which it unveils a distinctive wavy, bluish-white, linear fluorescence upon illumination.2

Functionally, the Wood lamp operates by subjecting phosphors to UV light within the wavelength range of 320 to 400 nm, inducing fluorescence in substances such as collagen and elastin. In the context of vitiligo, this process manifests as a preferential chalk white fluorescence in areas lacking melanin.1

Despite its demonstrated effectiveness, the Wood lamp is not without limitations. It comes with a notable financial investment ranging from $70 to $500, requires periodic maintenance such as light bulb replacements, and can be unwieldy.3 Furthermore, its reliance on a power source poses a challenge in settings where immediate access to convenient power outlets is limited, such as inpatient and rural dermatology clinics. These limitations underscore the need for alternative solutions and innovations to address challenges and ensure accessibility in diverse health care environments.

The Tools

Free smartphone applications (apps), such as Ultraviolet Light-UV Lamp by AppBrain or Blacklight UV Light Simulator by That Smile, can simulate UV light and functionally serve as a Wood lamp.

The Technique

UV light apps use LED or organic LED screen pixels to emit a blue light equivalent at 467 nm.4 Although these apps are not designed specifically for dermatologic uses, they are mostly free, widely available for Android and iPhone users, and portable. Importantly, they can demonstrate good performance in visualizing vitiligo, as shown in Figure 1—albeit perhaps not reaching the same level as the Wood lamp (Figure 2).

FIGURE 1. A and B, Depigmented patches of vitiligo on the skin are visualized with a free UV light smartphone application, respectively.

FIGURE 2. A and B, The same depigmented patches of vitiligo are visualized with a free UV light smartphone application vs a Wood lamp, respectively.

Because these UV light apps are not regulated and their efficacy for medical use has not been firmly established, the Wood lamp remains the gold standard. Therefore, we propose the use of UV light apps in situations when a Wood lamp is not available or convenient, such as in rural, inpatient, or international health care settings.

Practice Implications

Exploring and adopting these free alternatives can contribute to improved accessibility and diagnostic capabilities in diverse health care environments, particularly for communities facing financial constraints. Continued research and validation of these apps in clinical settings will be essential to establish their reliability and effectiveness in enhancing diagnostic practices.

References
  1. Dyer JM, Foy VM. Revealing the unseen: a review of Wood’s lamp in dermatology. J Clin Aesthet Dermatol. 2022;15:25-30.
  2. Scanni G. Facilitations in the clinical diagnosis of human scabies through the use of ultraviolet light (UV-scab scanning): a case-series study. Trop Med Infect Dis. 2022;7:422. doi:10.3390/tropicalmed7120422
  3. USA Medical and Surgical Supplies. Top 9 medical diagnostic applications for a Woods lamp. February 26, 2019. Accessed May 20, 2024.
  4. Huang Y, Hsiang E-L, Deng M-Y, et al. Mini-led, micro-led and OLED displays: present status and future perspectives. Light Sci Appl. 2020;9:105. doi:10.1038/s41377-020-0341-9
Article PDF
Author and Disclosure Information

 

Ruth Zagales is from the Indiana University School of Medicine, Indianapolis. Dr. Korman is from the Department of Dermatology, The Ohio State University Wexner Medical Center, Columbus.

The authors report no conflict of interest.

Correspondence: Abraham M. Korman, MD, 540 Office Center Pl, Ste 240, Columbus, OH 43230 ([email protected]).

Cutis. 2024 June;113(6):271-272. doi:10.12788/cutis.1026

Issue
Cutis - 113(6)
Publications
Topics
Page Number
271-272
Sections
Author and Disclosure Information

 

Ruth Zagales is from the Indiana University School of Medicine, Indianapolis. Dr. Korman is from the Department of Dermatology, The Ohio State University Wexner Medical Center, Columbus.

The authors report no conflict of interest.

Correspondence: Abraham M. Korman, MD, 540 Office Center Pl, Ste 240, Columbus, OH 43230 ([email protected]).

Cutis. 2024 June;113(6):271-272. doi:10.12788/cutis.1026

Author and Disclosure Information

 

Ruth Zagales is from the Indiana University School of Medicine, Indianapolis. Dr. Korman is from the Department of Dermatology, The Ohio State University Wexner Medical Center, Columbus.

The authors report no conflict of interest.

Correspondence: Abraham M. Korman, MD, 540 Office Center Pl, Ste 240, Columbus, OH 43230 ([email protected]).

Cutis. 2024 June;113(6):271-272. doi:10.12788/cutis.1026

Article PDF
Article PDF

Practice Gap

The Wood lamp commonly is used as a diagnostic tool for pigmentary skin conditions (eg, vitiligo) or skin conditions that exhibit fluorescence (eg, erythrasma).1 Recently, its diagnostic efficacy has extended to scabies, in which it unveils a distinctive wavy, bluish-white, linear fluorescence upon illumination.2

Functionally, the Wood lamp operates by subjecting phosphors to UV light within the wavelength range of 320 to 400 nm, inducing fluorescence in substances such as collagen and elastin. In the context of vitiligo, this process manifests as a preferential chalk white fluorescence in areas lacking melanin.1

Despite its demonstrated effectiveness, the Wood lamp is not without limitations. It comes with a notable financial investment ranging from $70 to $500, requires periodic maintenance such as light bulb replacements, and can be unwieldy.3 Furthermore, its reliance on a power source poses a challenge in settings where immediate access to convenient power outlets is limited, such as inpatient and rural dermatology clinics. These limitations underscore the need for alternative solutions and innovations to address challenges and ensure accessibility in diverse health care environments.

The Tools

Free smartphone applications (apps), such as Ultraviolet Light-UV Lamp by AppBrain or Blacklight UV Light Simulator by That Smile, can simulate UV light and functionally serve as a Wood lamp.

The Technique

UV light apps use LED or organic LED screen pixels to emit a blue light equivalent at 467 nm.4 Although these apps are not designed specifically for dermatologic uses, they are mostly free, widely available for Android and iPhone users, and portable. Importantly, they can demonstrate good performance in visualizing vitiligo, as shown in Figure 1—albeit perhaps not reaching the same level as the Wood lamp (Figure 2).

FIGURE 1. A and B, Depigmented patches of vitiligo on the skin are visualized with a free UV light smartphone application, respectively.

FIGURE 2. A and B, The same depigmented patches of vitiligo are visualized with a free UV light smartphone application vs a Wood lamp, respectively.

Because these UV light apps are not regulated and their efficacy for medical use has not been firmly established, the Wood lamp remains the gold standard. Therefore, we propose the use of UV light apps in situations when a Wood lamp is not available or convenient, such as in rural, inpatient, or international health care settings.

Practice Implications

Exploring and adopting these free alternatives can contribute to improved accessibility and diagnostic capabilities in diverse health care environments, particularly for communities facing financial constraints. Continued research and validation of these apps in clinical settings will be essential to establish their reliability and effectiveness in enhancing diagnostic practices.

Practice Gap

The Wood lamp commonly is used as a diagnostic tool for pigmentary skin conditions (eg, vitiligo) or skin conditions that exhibit fluorescence (eg, erythrasma).1 Recently, its diagnostic efficacy has extended to scabies, in which it unveils a distinctive wavy, bluish-white, linear fluorescence upon illumination.2

Functionally, the Wood lamp operates by subjecting phosphors to UV light within the wavelength range of 320 to 400 nm, inducing fluorescence in substances such as collagen and elastin. In the context of vitiligo, this process manifests as a preferential chalk white fluorescence in areas lacking melanin.1

Despite its demonstrated effectiveness, the Wood lamp is not without limitations. It comes with a notable financial investment ranging from $70 to $500, requires periodic maintenance such as light bulb replacements, and can be unwieldy.3 Furthermore, its reliance on a power source poses a challenge in settings where immediate access to convenient power outlets is limited, such as inpatient and rural dermatology clinics. These limitations underscore the need for alternative solutions and innovations to address challenges and ensure accessibility in diverse health care environments.

The Tools

Free smartphone applications (apps), such as Ultraviolet Light-UV Lamp by AppBrain or Blacklight UV Light Simulator by That Smile, can simulate UV light and functionally serve as a Wood lamp.

The Technique

UV light apps use LED or organic LED screen pixels to emit a blue light equivalent at 467 nm.4 Although these apps are not designed specifically for dermatologic uses, they are mostly free, widely available for Android and iPhone users, and portable. Importantly, they can demonstrate good performance in visualizing vitiligo, as shown in Figure 1—albeit perhaps not reaching the same level as the Wood lamp (Figure 2).

FIGURE 1. A and B, Depigmented patches of vitiligo on the skin are visualized with a free UV light smartphone application, respectively.

FIGURE 2. A and B, The same depigmented patches of vitiligo are visualized with a free UV light smartphone application vs a Wood lamp, respectively.

Because these UV light apps are not regulated and their efficacy for medical use has not been firmly established, the Wood lamp remains the gold standard. Therefore, we propose the use of UV light apps in situations when a Wood lamp is not available or convenient, such as in rural, inpatient, or international health care settings.

Practice Implications

Exploring and adopting these free alternatives can contribute to improved accessibility and diagnostic capabilities in diverse health care environments, particularly for communities facing financial constraints. Continued research and validation of these apps in clinical settings will be essential to establish their reliability and effectiveness in enhancing diagnostic practices.

References
  1. Dyer JM, Foy VM. Revealing the unseen: a review of Wood’s lamp in dermatology. J Clin Aesthet Dermatol. 2022;15:25-30.
  2. Scanni G. Facilitations in the clinical diagnosis of human scabies through the use of ultraviolet light (UV-scab scanning): a case-series study. Trop Med Infect Dis. 2022;7:422. doi:10.3390/tropicalmed7120422
  3. USA Medical and Surgical Supplies. Top 9 medical diagnostic applications for a Woods lamp. February 26, 2019. Accessed May 20, 2024.
  4. Huang Y, Hsiang E-L, Deng M-Y, et al. Mini-led, micro-led and OLED displays: present status and future perspectives. Light Sci Appl. 2020;9:105. doi:10.1038/s41377-020-0341-9
References
  1. Dyer JM, Foy VM. Revealing the unseen: a review of Wood’s lamp in dermatology. J Clin Aesthet Dermatol. 2022;15:25-30.
  2. Scanni G. Facilitations in the clinical diagnosis of human scabies through the use of ultraviolet light (UV-scab scanning): a case-series study. Trop Med Infect Dis. 2022;7:422. doi:10.3390/tropicalmed7120422
  3. USA Medical and Surgical Supplies. Top 9 medical diagnostic applications for a Woods lamp. February 26, 2019. Accessed May 20, 2024.
  4. Huang Y, Hsiang E-L, Deng M-Y, et al. Mini-led, micro-led and OLED displays: present status and future perspectives. Light Sci Appl. 2020;9:105. doi:10.1038/s41377-020-0341-9
Issue
Cutis - 113(6)
Issue
Cutis - 113(6)
Page Number
271-272
Page Number
271-272
Publications
Publications
Topics
Article Type
Display Headline
Need a Wood Lamp Alternative? Grab Your Smartphone
Display Headline
Need a Wood Lamp Alternative? Grab Your Smartphone
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Use ProPublica
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article
Article PDF Media

A Structured Approach for the Management of Orodynia (Burning Mouth Syndrome)

Article Type
Changed
Display Headline
A Structured Approach for the Management of Orodynia (Burning Mouth Syndrome)

Practice Gap

Orodynia (OD)—together with glossodynia colloquially termed “burning mouth syndrome”—is a chronic disorder characterized by a burning sensation within the oral cavity without objective clinical signs. It is most common in perimenopausal and postmenopausal women.1,2

Orodynia is a diagnosis of exclusion and is considered after 4 to 6 months of normal imaging and laboratory test results.1,2 Its pathophysiology is poorly understood, as it can be intermittent or continuous, manifest with a variety of symptoms, and affect various entities of the oral cavity.3,4 The most common structure affected is the tongue, and symptoms may include xerostomia, dysgeusia, and discomfort.1,2 Orodynia is a frustrating condition, as many patients do not respond to treatment and experience symptoms for years.1-4

The current approach to management of OD typically involves a combination of psychosocial strategies and pharmacologic agents. The psychosocial component consists of coping mechanisms (eg, stress management techniques and behavioral therapies) aimed at alleviating the psychological impact of the condition. Pharmacologic agents such as antidepressants, anticonvulsants, and topical medications often are prescribed to address neuropathic pain and dry mouth symptoms.1,2 Additionally, oral rinses, saliva substitutes, and dietary supplements may be recommended to counteract the discomfort associated with xerostomia.1,2 However, there is no stepwise protocol, leaving these treatments to be trialed in a disorganized manner.2

The Tools

In our unique approach to managing OD, physicians may employ a variety of tools, including autoantibody profiles, noninvasive salivary gland analysis, saliva analysis, patch testing for allergens, and—if deemed necessary—a minor salivary gland biopsy. The use of specific prescription medications is included in the later stages of our approach.

The Technique

First, exclude inflammatory conditions such as geographic tongue, oral lichen planus, autoimmune bullous disorders, and other treatable conditions such as dyspepsia and Sjögren syndrome using the tools described above. Noninvasive modalities should be exhausted first, and dermatologists/clinicians should exercise clinical judgement to determine whether all options should be trialed, including more invasive/costly ones.

If symptoms persist, clinicians may want to obtain a culture for oral candida. If results are positive, candida may be treated quickly with oral fluconazole. If that treatment fails and fissuring is present, advise the patient on treating the tongue; we recommend lightly brushing the tongue once daily with a hydrogen peroxide 3% solution, followed by rinsing. Next, the patient can allow an active probiotic yogurt to sit on the tongue for at least 1 minute to repopulate it with healthy oral bacteria.

If symptoms persist, prescribe gabapentin 100 to 300 mg to be taken at bedtime. Cevimeline 30 mg 3 times daily can be added to treat symptoms of xerostomia. As a last resort, a low daily dose of trifluoperazine 1 to 2 mg may alleviate the dysesthesia of OD. Because this medication is an antipsychotic, there is an increased risk for adverse effects such as tardive dyskinesia; however, given that we recommend using at most one-twentieth of the dose recommended for psychiatric illnesses such as schizophrenia, the risk appears to be minimal.5

We have found this protocol to be more structured, and in our practice, it has led to better outcomes than previously described therapeutic interventions.

Practice Implications

As a chronic condition, OD can be frustrating for patients, as many of them have attempted multiple treatments without success. It also may be challenging for dermatologists who are unfamiliar with its management. This approach to OD provides simple step-by-step diagnostic and therapeutic plans for a condition with an often-uncertain etiology and stubborn response to initial treatments. By following this protocol, dermatologists can be confident in their ability to help patients find relief from OD.

References
  1. Klein B, Thoppay JR, De Rossi SS, et al. Burning mouth syndrome. Dermatol Clin. 2020;38:477-483. doi:10.1016/j.det.2020.05.008
  2. Bender SD. Burning mouth syndrome. Dent Clin North Am. 2018;62:585-596. doi:10.1016/j.cden.2018.05.006
  3. Javali MA. Burning mouth syndrome: an enigmatic disorder. Kathmandu Univ Med J. 2013;11:175-178. doi:10.3126/kumj.v11i2.12498
  4. Sardella A, Lodi G, Demarosi F, et al. Burning mouth syndrome: a retrospective study investigating spontaneous remission and response to treatments. Oral Dis. 2006;12:152-155. doi:10.1111/j.1601-0825.2005.01174
  5. Macdonald R, Watts TP. Trifluoperazine dihydrochloride (stelazine) in paranoid schizophrenia. Br Med J. 1959;1:549-550. doi:10.1136/bmj.1.5121.549
Article PDF
Author and Disclosure Information

Dane J. Markham is from the Mayo Clinic Alix School of Medicine, Jacksonville, Florida. Taylor S. Davis is from the Saint Louis University School of Medicine, Missouri. Max E. Oscherwitz is from the Heersink School of Medicine, University of Alabama, Birmingham. Dr. Jorizzo is from the Department of Dermatology, Wake Forest University, Winston-Salem, North Carolina.

The authors report no conflict of interest.

Correspondence: Joseph L. Jorizzo, MD, 4618 Country Club Rd, Winston-Salem, NC 27104 ([email protected]).

Issue
Cutis - 113(5)
Publications
Topics
Page Number
224-225
Sections
Author and Disclosure Information

Dane J. Markham is from the Mayo Clinic Alix School of Medicine, Jacksonville, Florida. Taylor S. Davis is from the Saint Louis University School of Medicine, Missouri. Max E. Oscherwitz is from the Heersink School of Medicine, University of Alabama, Birmingham. Dr. Jorizzo is from the Department of Dermatology, Wake Forest University, Winston-Salem, North Carolina.

The authors report no conflict of interest.

Correspondence: Joseph L. Jorizzo, MD, 4618 Country Club Rd, Winston-Salem, NC 27104 ([email protected]).

Author and Disclosure Information

Dane J. Markham is from the Mayo Clinic Alix School of Medicine, Jacksonville, Florida. Taylor S. Davis is from the Saint Louis University School of Medicine, Missouri. Max E. Oscherwitz is from the Heersink School of Medicine, University of Alabama, Birmingham. Dr. Jorizzo is from the Department of Dermatology, Wake Forest University, Winston-Salem, North Carolina.

The authors report no conflict of interest.

Correspondence: Joseph L. Jorizzo, MD, 4618 Country Club Rd, Winston-Salem, NC 27104 ([email protected]).

Article PDF
Article PDF

Practice Gap

Orodynia (OD)—together with glossodynia colloquially termed “burning mouth syndrome”—is a chronic disorder characterized by a burning sensation within the oral cavity without objective clinical signs. It is most common in perimenopausal and postmenopausal women.1,2

Orodynia is a diagnosis of exclusion and is considered after 4 to 6 months of normal imaging and laboratory test results.1,2 Its pathophysiology is poorly understood, as it can be intermittent or continuous, manifest with a variety of symptoms, and affect various entities of the oral cavity.3,4 The most common structure affected is the tongue, and symptoms may include xerostomia, dysgeusia, and discomfort.1,2 Orodynia is a frustrating condition, as many patients do not respond to treatment and experience symptoms for years.1-4

The current approach to management of OD typically involves a combination of psychosocial strategies and pharmacologic agents. The psychosocial component consists of coping mechanisms (eg, stress management techniques and behavioral therapies) aimed at alleviating the psychological impact of the condition. Pharmacologic agents such as antidepressants, anticonvulsants, and topical medications often are prescribed to address neuropathic pain and dry mouth symptoms.1,2 Additionally, oral rinses, saliva substitutes, and dietary supplements may be recommended to counteract the discomfort associated with xerostomia.1,2 However, there is no stepwise protocol, leaving these treatments to be trialed in a disorganized manner.2

The Tools

In our unique approach to managing OD, physicians may employ a variety of tools, including autoantibody profiles, noninvasive salivary gland analysis, saliva analysis, patch testing for allergens, and—if deemed necessary—a minor salivary gland biopsy. The use of specific prescription medications is included in the later stages of our approach.

The Technique

First, exclude inflammatory conditions such as geographic tongue, oral lichen planus, autoimmune bullous disorders, and other treatable conditions such as dyspepsia and Sjögren syndrome using the tools described above. Noninvasive modalities should be exhausted first, and dermatologists/clinicians should exercise clinical judgement to determine whether all options should be trialed, including more invasive/costly ones.

If symptoms persist, clinicians may want to obtain a culture for oral candida. If results are positive, candida may be treated quickly with oral fluconazole. If that treatment fails and fissuring is present, advise the patient on treating the tongue; we recommend lightly brushing the tongue once daily with a hydrogen peroxide 3% solution, followed by rinsing. Next, the patient can allow an active probiotic yogurt to sit on the tongue for at least 1 minute to repopulate it with healthy oral bacteria.

If symptoms persist, prescribe gabapentin 100 to 300 mg to be taken at bedtime. Cevimeline 30 mg 3 times daily can be added to treat symptoms of xerostomia. As a last resort, a low daily dose of trifluoperazine 1 to 2 mg may alleviate the dysesthesia of OD. Because this medication is an antipsychotic, there is an increased risk for adverse effects such as tardive dyskinesia; however, given that we recommend using at most one-twentieth of the dose recommended for psychiatric illnesses such as schizophrenia, the risk appears to be minimal.5

We have found this protocol to be more structured, and in our practice, it has led to better outcomes than previously described therapeutic interventions.

Practice Implications

As a chronic condition, OD can be frustrating for patients, as many of them have attempted multiple treatments without success. It also may be challenging for dermatologists who are unfamiliar with its management. This approach to OD provides simple step-by-step diagnostic and therapeutic plans for a condition with an often-uncertain etiology and stubborn response to initial treatments. By following this protocol, dermatologists can be confident in their ability to help patients find relief from OD.

Practice Gap

Orodynia (OD)—together with glossodynia colloquially termed “burning mouth syndrome”—is a chronic disorder characterized by a burning sensation within the oral cavity without objective clinical signs. It is most common in perimenopausal and postmenopausal women.1,2

Orodynia is a diagnosis of exclusion and is considered after 4 to 6 months of normal imaging and laboratory test results.1,2 Its pathophysiology is poorly understood, as it can be intermittent or continuous, manifest with a variety of symptoms, and affect various entities of the oral cavity.3,4 The most common structure affected is the tongue, and symptoms may include xerostomia, dysgeusia, and discomfort.1,2 Orodynia is a frustrating condition, as many patients do not respond to treatment and experience symptoms for years.1-4

The current approach to management of OD typically involves a combination of psychosocial strategies and pharmacologic agents. The psychosocial component consists of coping mechanisms (eg, stress management techniques and behavioral therapies) aimed at alleviating the psychological impact of the condition. Pharmacologic agents such as antidepressants, anticonvulsants, and topical medications often are prescribed to address neuropathic pain and dry mouth symptoms.1,2 Additionally, oral rinses, saliva substitutes, and dietary supplements may be recommended to counteract the discomfort associated with xerostomia.1,2 However, there is no stepwise protocol, leaving these treatments to be trialed in a disorganized manner.2

The Tools

In our unique approach to managing OD, physicians may employ a variety of tools, including autoantibody profiles, noninvasive salivary gland analysis, saliva analysis, patch testing for allergens, and—if deemed necessary—a minor salivary gland biopsy. The use of specific prescription medications is included in the later stages of our approach.

The Technique

First, exclude inflammatory conditions such as geographic tongue, oral lichen planus, autoimmune bullous disorders, and other treatable conditions such as dyspepsia and Sjögren syndrome using the tools described above. Noninvasive modalities should be exhausted first, and dermatologists/clinicians should exercise clinical judgement to determine whether all options should be trialed, including more invasive/costly ones.

If symptoms persist, clinicians may want to obtain a culture for oral candida. If results are positive, candida may be treated quickly with oral fluconazole. If that treatment fails and fissuring is present, advise the patient on treating the tongue; we recommend lightly brushing the tongue once daily with a hydrogen peroxide 3% solution, followed by rinsing. Next, the patient can allow an active probiotic yogurt to sit on the tongue for at least 1 minute to repopulate it with healthy oral bacteria.

If symptoms persist, prescribe gabapentin 100 to 300 mg to be taken at bedtime. Cevimeline 30 mg 3 times daily can be added to treat symptoms of xerostomia. As a last resort, a low daily dose of trifluoperazine 1 to 2 mg may alleviate the dysesthesia of OD. Because this medication is an antipsychotic, there is an increased risk for adverse effects such as tardive dyskinesia; however, given that we recommend using at most one-twentieth of the dose recommended for psychiatric illnesses such as schizophrenia, the risk appears to be minimal.5

We have found this protocol to be more structured, and in our practice, it has led to better outcomes than previously described therapeutic interventions.

Practice Implications

As a chronic condition, OD can be frustrating for patients, as many of them have attempted multiple treatments without success. It also may be challenging for dermatologists who are unfamiliar with its management. This approach to OD provides simple step-by-step diagnostic and therapeutic plans for a condition with an often-uncertain etiology and stubborn response to initial treatments. By following this protocol, dermatologists can be confident in their ability to help patients find relief from OD.

References
  1. Klein B, Thoppay JR, De Rossi SS, et al. Burning mouth syndrome. Dermatol Clin. 2020;38:477-483. doi:10.1016/j.det.2020.05.008
  2. Bender SD. Burning mouth syndrome. Dent Clin North Am. 2018;62:585-596. doi:10.1016/j.cden.2018.05.006
  3. Javali MA. Burning mouth syndrome: an enigmatic disorder. Kathmandu Univ Med J. 2013;11:175-178. doi:10.3126/kumj.v11i2.12498
  4. Sardella A, Lodi G, Demarosi F, et al. Burning mouth syndrome: a retrospective study investigating spontaneous remission and response to treatments. Oral Dis. 2006;12:152-155. doi:10.1111/j.1601-0825.2005.01174
  5. Macdonald R, Watts TP. Trifluoperazine dihydrochloride (stelazine) in paranoid schizophrenia. Br Med J. 1959;1:549-550. doi:10.1136/bmj.1.5121.549
References
  1. Klein B, Thoppay JR, De Rossi SS, et al. Burning mouth syndrome. Dermatol Clin. 2020;38:477-483. doi:10.1016/j.det.2020.05.008
  2. Bender SD. Burning mouth syndrome. Dent Clin North Am. 2018;62:585-596. doi:10.1016/j.cden.2018.05.006
  3. Javali MA. Burning mouth syndrome: an enigmatic disorder. Kathmandu Univ Med J. 2013;11:175-178. doi:10.3126/kumj.v11i2.12498
  4. Sardella A, Lodi G, Demarosi F, et al. Burning mouth syndrome: a retrospective study investigating spontaneous remission and response to treatments. Oral Dis. 2006;12:152-155. doi:10.1111/j.1601-0825.2005.01174
  5. Macdonald R, Watts TP. Trifluoperazine dihydrochloride (stelazine) in paranoid schizophrenia. Br Med J. 1959;1:549-550. doi:10.1136/bmj.1.5121.549
Issue
Cutis - 113(5)
Issue
Cutis - 113(5)
Page Number
224-225
Page Number
224-225
Publications
Publications
Topics
Article Type
Display Headline
A Structured Approach for the Management of Orodynia (Burning Mouth Syndrome)
Display Headline
A Structured Approach for the Management of Orodynia (Burning Mouth Syndrome)
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Use ProPublica
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article
Article PDF Media

Enhancing Cosmetic and Functional Improvement of Recalcitrant Nail Lichen Planus With Resin Nail

Article Type
Changed
Display Headline
Enhancing Cosmetic and Functional Improvement of Recalcitrant Nail Lichen Planus With Resin Nail

Practice Gap

Lichen planus (LP)—a chronic inflammatory disorder affecting the nails—is prevalent in 10% to 15% of patients and is more common in the fingernails than toenails. Clinical manifestation includes longitudinal ridges, nail plate atrophy, and splitting, which all contribute to cosmetic disfigurement and difficulty with functionality. Quality of life and daily activities may be impacted profoundly.1 First-line therapies include intralesional and systemic corticosteroids; however, efficacy is limited and recurrence is common.1,2 Lichen planus is one of the few conditions that may cause permanent and debilitating nail loss.

Tools

A resin nail can be used to improve cosmetic appearance and functionality in patients with recalcitrant nail LP. The composite resin creates a flexible nonporous nail and allows the underlying natural nail to grow. Application of resin nails has been used for toenail onychodystrophies to improve cosmesis and functionality but has not been reported for fingernails. The resin typically lasts 6 to 8 weeks on toenails.

 

The Technique

Application of a resin nail involves several steps (see video online). First, the affected nail should be debrided and a bonding agent applied. Next, multiple layers of resin are applied until the patient’s desired thickness is achieved (typically 2 layers), followed by a sealing agent. Finally, the nail is cured with UV light. We recommend applying sunscreen to the hand(s) prior to curing with UV light. The liquid resin allows the nail to be customized to the patient’s desired length and shape. The overall procedure takes approximately 20 minutes for a single nail.

We applied resin nail to the thumbnail of a 46-year-old woman with recalcitrant isolated nail LP of 7 years’ duration (Figure). She previously had difficulties performing everyday activities, and the resin improved her functionality. She also was pleased with the cosmetic appearance. After 2 weeks, the resin started falling off with corresponding natural nail growth. The patient denied any adverse events.

A, Lichen planus of the thumbnail before application of resin nail. B, Fingernail after application of resin nail.
A, Lichen planus of the thumbnail before application of resin nail. B, Fingernail after application of resin nail.

Practice Implications

Resin nail application may serve as a temporary solution to improve cosmesis and functionality in patients with recalcitrant nail LP. As shown in our patient, the resin may fall off faster on the fingernails than the toenails, likely because of the faster growth rate of fingernails and more frequent exposure from daily activities. Further studies of resin nail application for the fingernails are needed to establish duration in patients with varying levels of activity (eg, washing dishes, woodworking).

Because the resin nail may be removed easily at any time, resin nail application does not interfere with treatments such as intralesional steroid injections. For patients using a topical medication regimen, the resin nail may be applied slightly distal to the cuticle so that the medication can still be applied by the proximal nail fold of the underlying natural nail.

The resin nail should be kept short and removed after 2 to 4 weeks for the fingernails and 6 to 8 weeks for the toenails to examine the underlying natural nail. Patients may go about their daily activities with the resin nail, including applying nail polish to the resin nail, bathing, and swimming. Resin nail application may complement medical treatments and improve quality of life for patients with nail LP.

References
  1. Gupta MK, Lipner SR. Review of nail lichen planus: epidemiology, pathogenesis, diagnosis, and treatment. Dermatol Clin. 2021;39:221-230. doi:10.1016/j.det.2020.12.002
  2. Iorizzo M, Tosti A, Starace M, et al. Isolated nail lichen planus: an expert consensus on treatment of the classical form. J Am Acad Dermatol. 2020;83:1717-1723. doi:10.1016/j.jaad.2020.02.056
Article PDF
Author and Disclosure Information

Kaya L. Curtis is from Weill Cornell Medical College, New York, NY. Drs. Ricardo and Lipner are from the Department of Dermatology, Weill Cornell Medicine, New York, NY.

Kaya L. Curtis and Dr. Richard report no conflicts of interest. Dr. Lipner has served as a consultant for BelleTorus Corporation, Eli Lilly and Company, Moberg Pharmaceuticals, and Ortho-Dermatologics.

The video is available online at www.mdedge.com/dermatology.

Correspondence: Shari R. Lipner, MD, PhD, 1305 York Ave, New York, NY 10021 ([email protected]).

Issue
Cutis - 113(4)
Publications
Topics
Page Number
191-192
Sections
Author and Disclosure Information

Kaya L. Curtis is from Weill Cornell Medical College, New York, NY. Drs. Ricardo and Lipner are from the Department of Dermatology, Weill Cornell Medicine, New York, NY.

Kaya L. Curtis and Dr. Richard report no conflicts of interest. Dr. Lipner has served as a consultant for BelleTorus Corporation, Eli Lilly and Company, Moberg Pharmaceuticals, and Ortho-Dermatologics.

The video is available online at www.mdedge.com/dermatology.

Correspondence: Shari R. Lipner, MD, PhD, 1305 York Ave, New York, NY 10021 ([email protected]).

Author and Disclosure Information

Kaya L. Curtis is from Weill Cornell Medical College, New York, NY. Drs. Ricardo and Lipner are from the Department of Dermatology, Weill Cornell Medicine, New York, NY.

Kaya L. Curtis and Dr. Richard report no conflicts of interest. Dr. Lipner has served as a consultant for BelleTorus Corporation, Eli Lilly and Company, Moberg Pharmaceuticals, and Ortho-Dermatologics.

The video is available online at www.mdedge.com/dermatology.

Correspondence: Shari R. Lipner, MD, PhD, 1305 York Ave, New York, NY 10021 ([email protected]).

Article PDF
Article PDF

Practice Gap

Lichen planus (LP)—a chronic inflammatory disorder affecting the nails—is prevalent in 10% to 15% of patients and is more common in the fingernails than toenails. Clinical manifestation includes longitudinal ridges, nail plate atrophy, and splitting, which all contribute to cosmetic disfigurement and difficulty with functionality. Quality of life and daily activities may be impacted profoundly.1 First-line therapies include intralesional and systemic corticosteroids; however, efficacy is limited and recurrence is common.1,2 Lichen planus is one of the few conditions that may cause permanent and debilitating nail loss.

Tools

A resin nail can be used to improve cosmetic appearance and functionality in patients with recalcitrant nail LP. The composite resin creates a flexible nonporous nail and allows the underlying natural nail to grow. Application of resin nails has been used for toenail onychodystrophies to improve cosmesis and functionality but has not been reported for fingernails. The resin typically lasts 6 to 8 weeks on toenails.

 

The Technique

Application of a resin nail involves several steps (see video online). First, the affected nail should be debrided and a bonding agent applied. Next, multiple layers of resin are applied until the patient’s desired thickness is achieved (typically 2 layers), followed by a sealing agent. Finally, the nail is cured with UV light. We recommend applying sunscreen to the hand(s) prior to curing with UV light. The liquid resin allows the nail to be customized to the patient’s desired length and shape. The overall procedure takes approximately 20 minutes for a single nail.

We applied resin nail to the thumbnail of a 46-year-old woman with recalcitrant isolated nail LP of 7 years’ duration (Figure). She previously had difficulties performing everyday activities, and the resin improved her functionality. She also was pleased with the cosmetic appearance. After 2 weeks, the resin started falling off with corresponding natural nail growth. The patient denied any adverse events.

A, Lichen planus of the thumbnail before application of resin nail. B, Fingernail after application of resin nail.
A, Lichen planus of the thumbnail before application of resin nail. B, Fingernail after application of resin nail.

Practice Implications

Resin nail application may serve as a temporary solution to improve cosmesis and functionality in patients with recalcitrant nail LP. As shown in our patient, the resin may fall off faster on the fingernails than the toenails, likely because of the faster growth rate of fingernails and more frequent exposure from daily activities. Further studies of resin nail application for the fingernails are needed to establish duration in patients with varying levels of activity (eg, washing dishes, woodworking).

Because the resin nail may be removed easily at any time, resin nail application does not interfere with treatments such as intralesional steroid injections. For patients using a topical medication regimen, the resin nail may be applied slightly distal to the cuticle so that the medication can still be applied by the proximal nail fold of the underlying natural nail.

The resin nail should be kept short and removed after 2 to 4 weeks for the fingernails and 6 to 8 weeks for the toenails to examine the underlying natural nail. Patients may go about their daily activities with the resin nail, including applying nail polish to the resin nail, bathing, and swimming. Resin nail application may complement medical treatments and improve quality of life for patients with nail LP.

Practice Gap

Lichen planus (LP)—a chronic inflammatory disorder affecting the nails—is prevalent in 10% to 15% of patients and is more common in the fingernails than toenails. Clinical manifestation includes longitudinal ridges, nail plate atrophy, and splitting, which all contribute to cosmetic disfigurement and difficulty with functionality. Quality of life and daily activities may be impacted profoundly.1 First-line therapies include intralesional and systemic corticosteroids; however, efficacy is limited and recurrence is common.1,2 Lichen planus is one of the few conditions that may cause permanent and debilitating nail loss.

Tools

A resin nail can be used to improve cosmetic appearance and functionality in patients with recalcitrant nail LP. The composite resin creates a flexible nonporous nail and allows the underlying natural nail to grow. Application of resin nails has been used for toenail onychodystrophies to improve cosmesis and functionality but has not been reported for fingernails. The resin typically lasts 6 to 8 weeks on toenails.

 

The Technique

Application of a resin nail involves several steps (see video online). First, the affected nail should be debrided and a bonding agent applied. Next, multiple layers of resin are applied until the patient’s desired thickness is achieved (typically 2 layers), followed by a sealing agent. Finally, the nail is cured with UV light. We recommend applying sunscreen to the hand(s) prior to curing with UV light. The liquid resin allows the nail to be customized to the patient’s desired length and shape. The overall procedure takes approximately 20 minutes for a single nail.

We applied resin nail to the thumbnail of a 46-year-old woman with recalcitrant isolated nail LP of 7 years’ duration (Figure). She previously had difficulties performing everyday activities, and the resin improved her functionality. She also was pleased with the cosmetic appearance. After 2 weeks, the resin started falling off with corresponding natural nail growth. The patient denied any adverse events.

A, Lichen planus of the thumbnail before application of resin nail. B, Fingernail after application of resin nail.
A, Lichen planus of the thumbnail before application of resin nail. B, Fingernail after application of resin nail.

Practice Implications

Resin nail application may serve as a temporary solution to improve cosmesis and functionality in patients with recalcitrant nail LP. As shown in our patient, the resin may fall off faster on the fingernails than the toenails, likely because of the faster growth rate of fingernails and more frequent exposure from daily activities. Further studies of resin nail application for the fingernails are needed to establish duration in patients with varying levels of activity (eg, washing dishes, woodworking).

Because the resin nail may be removed easily at any time, resin nail application does not interfere with treatments such as intralesional steroid injections. For patients using a topical medication regimen, the resin nail may be applied slightly distal to the cuticle so that the medication can still be applied by the proximal nail fold of the underlying natural nail.

The resin nail should be kept short and removed after 2 to 4 weeks for the fingernails and 6 to 8 weeks for the toenails to examine the underlying natural nail. Patients may go about their daily activities with the resin nail, including applying nail polish to the resin nail, bathing, and swimming. Resin nail application may complement medical treatments and improve quality of life for patients with nail LP.

References
  1. Gupta MK, Lipner SR. Review of nail lichen planus: epidemiology, pathogenesis, diagnosis, and treatment. Dermatol Clin. 2021;39:221-230. doi:10.1016/j.det.2020.12.002
  2. Iorizzo M, Tosti A, Starace M, et al. Isolated nail lichen planus: an expert consensus on treatment of the classical form. J Am Acad Dermatol. 2020;83:1717-1723. doi:10.1016/j.jaad.2020.02.056
References
  1. Gupta MK, Lipner SR. Review of nail lichen planus: epidemiology, pathogenesis, diagnosis, and treatment. Dermatol Clin. 2021;39:221-230. doi:10.1016/j.det.2020.12.002
  2. Iorizzo M, Tosti A, Starace M, et al. Isolated nail lichen planus: an expert consensus on treatment of the classical form. J Am Acad Dermatol. 2020;83:1717-1723. doi:10.1016/j.jaad.2020.02.056
Issue
Cutis - 113(4)
Issue
Cutis - 113(4)
Page Number
191-192
Page Number
191-192
Publications
Publications
Topics
Article Type
Display Headline
Enhancing Cosmetic and Functional Improvement of Recalcitrant Nail Lichen Planus With Resin Nail
Display Headline
Enhancing Cosmetic and Functional Improvement of Recalcitrant Nail Lichen Planus With Resin Nail
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Use ProPublica
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article
Article PDF Media